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 The inflammatory nature of the tumor microenvironment provides a cytokine and 
chemokine rich proliferative environment.  Much of the responsibility of this environment 
is due to the production of Reactive Oxygen Species (ROS).  These studies examined 
   
 
 
the proliferative rich tumor environment from a new perspective of Nitric Oxide Synthase 
(NOS) dysregulation.  NOS’s have the ability to become uncoupled and generate 
superoxide in lieu of nitric oxide (NO).  A requirement of NOS for the production of NO 
is the cofactor tetrahydrobiopterin (BH4) and when it is missing NOS becomes 
uncoupled and turns into a peroxynitrite synthase.  Here I demonstrate that NOS is 
uncoupled in tumor cells due to depleted BH4 levels.  This uncoupling leads to 
decreased NO signaling and increased pro-inflammatory, pro-survival, signaling as a 
result of the increased generation of ROS/RNS from uncoupled NOS activity.  I was 
able to recouple NOS through exogenous BH4 both in vitro and in vivo, reducing 
ROS/RNS and reestablishing NO signaling through cGMP protein associated kinase.  
Reduction of ROS/RNS resulted in the reduced activity of two major constitutively active 
transcription factors in breast cancer cells, NFκB and STAT3.  In MCF-7 and MDA231 
cells I found that increased NO-dependent PKG signaling led to tumor cell toxicity 
mediated by downregulation of β-catenin.  Downregulation of β-catenin led to increased 
protein levels of p21 in MCF-7 and p27 in MDA 231cells, ultimately resulting in cell 
death.  These results suggest that there is potential for BH4 as a therapeutic agent 
since exogenous dietary BH4 ameliorates chemically induced colitis, and reduced 
azoxymethane (AOM) induced colon and spontaneously developing mammary 
carcinogenesis.  
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Chapter 1 
Background and Significance 
 
Inflammation and cancer 
The link between inflammation and cancer was proposed over a century ago 
when Virchow suggested that cancers tend to arise at sites of chronic inflammation [1].  
It has been suggested that tumors are wounds that do not heal.  Tissue injury is 
accompanied by enhancement of cell proliferation and inflammation, with both 
eventually subsiding.   In the case of initiated cells, the inflammatory microenvironment 
rich in growth factors acts as the perfect host [2].  Several cancers have been shown to 
arise from sites of infection and inflammation.  Colon cancer is the cancer most strongly 
associated with chronic inflammation.  Inflammatory bowel disease, such as Crohn’s 
and ulcerative colitis are linked to the formation of cancer.  Hepatitis C in the liver is an 
underlying cause in many liver carcinomas.  H. pylori infection has been linked to gastric 
cancer and HPV is a cause of nearly all cases of cervical cancer and is an important 
etiological factor in head and neck cancer [3, 4] 
Cancer can be broken down into three stages:  initiation, promotion, and 
progression.  Sites of chronic inflammation play a role in tumor cell initiation[5].  These 
sites contain a variety of cells including, macrophages, activated fibroblasts, leukocytes 
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and other phagocytic cells, capable of inducing DNA damage in cells through the 
generation of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS), 
such as peroxynitrite (ONOO-), a mutagenic agent [6].  These toxic insults can occur 
through direct interaction with DNA or by modulation of proteins involved in DNA repair.  
It has been demonstrated that enhanced chromosomal instability occurs through 
inhibition of BRCA-1 (gene responsible for DNA repair) by RNS which reduces the 
ability of cells to repair DNA double stand breaks leading to error-prone repair and 
mutagenesis [7].   Tumor promotion and progression is stimulated in an environment 
rich in inflammatory cells.  The tumor microenvironment is composed mainly of 
activated fibroblasts and infiltrating inflammatory cells.  These cells secrete proteolytic 
enzymes, cytokines and chemokines which are mitogenic for neoplastic cells promoting 
not only tumor cell growth, but stimulating angiogenesis and enabling metastatic 
spread.  Tumor associated macrophages (TAM’s) comprise a large proportion of the 
inflammatory infiltrates in neoplastic tissues.  Although these TAM’s are there to kill 
neoplastic cells, they also produce many of the factors required for tumor proliferation 
[8].  Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce the 
risk of developing and treating some cancers, including colon, lung and stomach and 
will be discussed more ahead [9, 10].    
Nitric Oxide generation and signaling 
 Nitric Oxide Synthases (NOSs) are a group of calcium/calmodulin responsive 
enzymes (eNOS (NOS III), nNOS (NOSI), and iNOS (NOSII)) that catalyze the 
production of NO (and L-citrulline) through the oxidation of L-arginine [11].  The 
synthesis of NO occurs through NOS dimers and requires the substrate arginine along 
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with NADPH and molecular oxygen (O2) as co-substrates.  Tetrahydrobiopterin, FAD 
and FMN are required cofactors [12].  Both NOS I and NOS III are constitutively 
expressed in neural cells and endothelial cells respectively and are responsible for a 
low basal level of NO synthesis.  NOS III is membrane associated and is constitutively 
expressed in endothelial cells and cardiac myocytes and is involved in maintaining 
vascular tone, platelet aggregation, angiogenesis and smooth muscle cell proliferation.  
NOS I is constitutively expressed in neurons and acts as a neurotransmitter in both the 
central and peripheral nervous system.  In skeletal muscle NOS I is responsible for 
producing large amounts of NO during contraction of skeletal muscle [13].  NOS II is 
found in a variety of cell types including fibroblasts, macrophages, dendritic cells, 
epithelial cells, and some cancer cells.  NOS II plays a role in host immunity and upon 
induction produces large amounts of NO, which in an inflammatory environment can 
react with O2
- leading to cell toxicity [14].  A large focus of the current research focuses 
on NO and production of ROS and RNS that in normal cells would be toxic but in tumor 
cells stimulates pro-survival pathways due to dysregulation in these pathways.       
NO generation and propagation of its signaling plays a major role in 
cardiovascular health.  Regulation of blood pressure and vascular tone along with 
inhibition of platelet aggregation and leukocyte adhesion are the main cardioprotective 
effects.  NO produced rapidly diffuses throughout cells and has many targets.  The 
binding of NO to the heme moiety of soluble guanylate cyclase (sGC) is the main 
physiologically relevant target of NO.  This binding results in the formation of 3,5-cyclic 
guanylate monophosphate (cGMP) from guanosine triphosphate (GTP).  cGMP is the 
principle messenger involved in vasodilation, neurotransmission and platelet 
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aggregation.   NO is the primary vasoregulator in mammalian cells and the generation 
of cGMP results in the subsequent activation of cGMP dependent protein kinase (PKG) 
leading to the phosphorylation of vasodilator-stimulated phosphoprotein (VASP) and the 
inositol 1,4,5-triphosphate receptor (IP3 receptor) resulting in vasodilation [15].  The 
binding of NO with sGC results in the formation of metal nitrosyls (Fe-NO) which are 
quite stable and occur rapidly.  NO reacts with myoglobin and hemoglobin in the same 
manner along with cytochrome P450’s [16].  DNA and lipid radicals are formed by the 
interaction of DNA and lipids with NO.   
 The cellular effects above are a direct result of the interaction of NO with a 
specific target, but NO can also have indirect effects.  Indirect effects typically occur at 
higher concentrations.  These effects occur when NO reacts with ROS, such as O2
-, 
generated through normal cellular processes and form biologically active molecules 
known as RNS and will be discussed in the next section.   
Under certain conditions NOS can become dysregulated and functions as a 
generator of O2
- as well as NO when NOS becomes uncoupled due to limited availability 
of its cofactor BH4 or reduced substrate, arginine.  When this occurs NOS becomes a 
generator of ONOO- resulting in a wide range of cell signaling implications.  The 
uncoupling of NOS’s is the focus of much of the following work and will therefore be 
discussed in much greater detail ahead. 
Redox Signaling 
ROS are chemically reactive molecules containing reactive oxygen derivatives.  
Historically ROS were viewed as the byproduct resulting from reactions involving 
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cellular oxygen metabolism and when they accumulated in cells they became toxic and 
had negative impacts on cells.  Now, ROS are viewed and studied as relevant signaling 
molecules.  ROS include radicals such as O2
-, hydroxyl (•OH), and peroxyl (RO2
-) that 
contain unpaired valence electrons.  There are also non-radical compounds such as 
H2O2 and HOCl which have volatile O-O bonds. 
 Normal cellular metabolism results in the production of ROS due to the activity of 
the electron transport chain.  Cells have their own antioxidant defense systems to 
combat damaging effects of ROS.  Superoxide dismutases (SODs) catalyze the 
dismutation of superoxide into oxygen and H2O2.  Cells then convert H2O2 to water by 
catalases, glutathione peroxidase and peroxiredoxins.  Redox signaling by O2
- is highly 
location specific as its lack of diffusibility and short half-life limit its range.  On the other 
hand H2O2 mediated signaling is able to occur throughout the cell as it can diffuse easily 
and is relatively stable compared to radical species, and is generally believed to be the 
predominant intracellular redox signaling molecule [17, 18]. 
 Production of ROS plays a major role in the induction of host defenses.  NADPH 
oxidases (NOXs) are activated in the membranes of neutrophils during respiratory burst 
and was originally identified as a source of the microbial oxidants generated [19].  
Platelets involved in wound repair release ROS to recruit additional platelets to the site 
of injury.  As was discussed previously this process can become problematic.  
Overstimulation of these species is a hallmark of many diseases.  NOX activity in 
arterial walls leads to macrophage recruitment causing them to adhere to the walls.  If 
this inflammatory process remains unchecked it can lead to atherosclerosis. 
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 As previously described, cancer cells exist in an inflammatory environment with 
high levels of ROS, which arise from TAM’s, increased metabolic activity and 
mitochondrial malfunction.  It has been demonstrated that ROS facilitates cancer cell 
survival through modulation of receptor tyrosine kinases (RTK’s) required for cell 
proliferation [20].  Many of these signaling pathways manipulated by ROS are actually 
manipulated by RNS which has become synonymous with ROS.  RNS are generated by 
reaction of ROS with NO.  ONOO-, produced from the reaction of NO with O2
-, is a 
powerful oxidizer which can react with amino acids, metal containing compounds, 
nucleic acids and plays a major role in cellular injury.  Cellular injury by ONOO- happens 
at levels of NO that approach SOD levels where NO outcompetes SOD for O2
- and 
generates toxic amounts of ONOO-.  At lower concentrations of ONOO- it rearranges 
mostly to nitrite/nitrate and represents a cytoprotective mechanism [21].  
Generation of RNS leads to altered cellular function through protein Tyr nitration 
and Cys S-nitrosylation or S-oxidation.  Tyrosine nitration involves the incorporation of a 
nitro group (-NO2) to the ring structure of tyrosine residues resulting in the formation of 
3-nitrotyrosine.   Biologically relevant protein Tyr nitration has been proposed to occur 
through several mechanisms: the generation of NO2 radicals, reaction of NO with tyrosyl 
radicals, and through generation of ONOO- [22].  Recent work has validated the role of 
Tyr nitration and Cys S-nitrosylation as relevant cellular signaling mechanisms.  Both 
processes are selective and reversible and these modifications can cause activation or 
inhibition of certain cellular pathways depending on the target [23, 24].  Nitration of 
Cytochrome C oxidase has been shown to inhibit mitochondrial respiration and our 
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studies demonstrate that nitration of I B  was critical for the IR-induced activation of the 
transcription factor, NF- B [25].   
As previously stated, many of the RTK’s and the phosphatases that regulate 
them are controlled by redox signaling.  This occurs through reactive thiols on cysteine 
residues in the protein.  Many of these cysteines are in the active sites of these kinases 
and phosphatases and their modification alters function.  Cys S-nitrosylation occurs 
through direct interaction of NO with the thiol group of cysteines resulting in the 
formation of a nitrosothiol (S-N=O).  Alternatively, formation of cysteine sulfenic acids in 
the presence of H2O2 has been demonstrated to regulate many of the proteins as well 
[26, 27].  A thorough review in the literature on redox regulation of receptors, such as 
the insulin receptor (IR), epidermal growth factor receptor (EGFR), and platelet-derived 
growth factor receptor (PDGFR) has been conducted [28].  There is much evidence that 
protein tyrosine phosphatases (PTPs) are regulated by this mechanism.  Formation of 
sulfenic acid has been demonstrated at the catalytic center of PTPs through exogenous 
H2O2 or H2O2 generated by mitogenic cells.  These PTPs are reactivated through 
reduction by GSH or reduced thioredoxin [29, 30].  SHP-1 and SHP-2 have been 
demonstrated by our laboratory and by others to be regulated by S-NO and sulfenic 
acid formation [31-33]. S-nitrosylation of the active site cysteine of Caspases has been 
shown to inhibit apoptosis in hepatocytes, endothelial cells, and tumor cells [34-36].  
Figure 1.1 describes a cycle where inflammation begets inflammation and how this 
cycle is active in promoting tumor development   
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Post-translational modifications on Cysteines can also be a marker for severe 
oxidative stress as persistent presence of H2O2 results in irreversible formation of 
sulfinic and sulfonic acids.  There are many examples of redox signaling through 
nitration, s-nitrosylation and s-oxidation and these will be the focus of much of our work.   
Nitirc Oxide as a cancer therapeutic 
NO has been shown to play a role in both tumor initiation and progression.  
Agents that induce NO or NO donors have been used clinically in cardiovascular 
diseases and recently have been researched for use in treatment of malignancies.  As a 
cancer therapeutic both anti-NO and NO-based anticancer treatments appear effective 
in several preclinical models.  NO can promote apoptosis in some cells, whereas it 
inhibits apoptosis in other cells.  This complexity is an indication of the importance of 
NO source (NO donors versus endogenous), location of that source, NO concentration, 
duration and cell type in understanding the cellular role of NO.  Pro-growth effects of NO 
have been established in several tumor types.  Tumor cells require a steady supply of 
oxygen, nutrients and growth factors which occurs through the production of NO from 
eNOS resulting in enhanced vascular relaxation and permeability.  Tumor cells that are 
not receiving this steady supply of nutrients typically exists in hypoxic areas.  Hypoxia 
exists within a tumor for a variety of reasons, including abnormal and insufficient 
vasculature leading to low intratumor blood flow.  Hypoxia in a solid tumor leads to the 
stabilization and activation of hypoxia inducible factor-1 (HIF-1).  Under normoxic 
conditions, HIF-1 is targeted for ubiquitination and subsequent proteasomal 
degradation, but activation during hypoxic conditions leads to the production of 
erythropoietin and vascular endothelial growth factor (VEGF) promoting tumor 
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vascularization [37].   Indeed, research has demonstrated that eNOS expression is up-
regulated in solid tumor vessels resulting in enhanced angiogenesis and that this occurs 
through VEGF and HIF-1 expression [38, 39].  It has also been demonstrated that NO 
production results in the activation of COX-2 leading to increased prostaglandin PGE2 
levels enhancing tumor vasculature permeability and facilitating angiogenesis [40].  This 
data would suggest that anti-NO treatments would be effective in containing tumor 
development and progression.  Bevacizumab is an anti-VEGF monoclonal antibody 
approved for the treatment of colorectal, breast, lung and glioblastoma that works by 
inhibiting angiogenesis through inhibition of NO production[41]. Curcumin is another 
compound that has shown promise in reducing the expression of angiogenic factors by 
way of inhibiting the pro-inflammatory NFκB pathway resulting in decreased COX-2 and 
VEGF [42, 43].  By inhibiting NFκB signaling, curcumin decreases iNOS expression.  
Our laboratory has demonstrated that the NOS inhibitor L-NNA inhibits tumor growth 
alone and in combination with radiation in squamous carcinoma xenografts by 
decreasing tumor blood flow [44].   
 Effective anti-tumor possibilities have been demonstrated for NO inducers or NO 
donors as well, either as a single agent or in combination with other chemotherapeutics.  
Initial studies that lead to NO as having anti-tumor activity involved the observation that 
murine activated macrophages, that synthesized nitrite and nitrate, were cytotoxic to 
tumor cells [45].  Since that time NO donors have become a useful tool to study the anti-
oncogenic effects in tumor biology.  NO-NSAID’s have shown promise as an anti-cancer 
agent.  NO donating aspirin (NO-ASA) displayed marked ability as a chemopreventive 
in colon cancer cells both in vitro and in vivo [46, 47].  NO-ASA was shown to be an 
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effective releaser of NO and treatment of HCT116 and HT-29 colon cancer cells 
resulted in inhibition of growth [48].  The results showed that the NO released modified 
a number of cell signaling members key in tumor cell signaling, including NFκB, β-
catenin and p53, all of which were shown to be S-nitrosylated.  The S-nitrosylation of 
the p65 subunit of NFκB resulted in decreased DNA binding [49].  As will be discussed 
later, NFκB is a pro-inflammatory and pro-survival transcription factor that is 
constitutively active in many cancers.   
 The NO donating prodrug, O2-(2,4-dintrophenyl) 1-[(4-ethoxycarbonyl)piperazin-
1-yl]diazen-1-ium-1,2-diolate (JS-K) is another NO donating compound that has shown 
promise as an anti-oncogenic agent in leukemia, renal, prostate and brain cancer cells 
[50, 51].  Jurkat T-Acute Lymphoblastic Leukemia Cells treated with JS-K showed a 
concentration dependent decrease in proliferation through a mechanism involving the S-
nitrosylation of β-catenin.  -catenin is a member of the Wnt signaling pathway and 
plays a role in cell proliferation through its regulation of Cyclin D1 (β-catenin will be 
discussed in more detail later) [52].    
Tumor hypoxia has been shown to be a source of drug resistance in tumor cells, 
and it has been demonstrated that NO can be used as a chemosensitizing agent in 
combination with other chemotherapeutics or as a radiosensitizer in combination with 
radiotherapy.  Exogenously administered NO donating drugs have been shown to 
reduce hypoxic conditions in tumors through an increase in tumor perfusion and that 
this increases the efficacy of other treatments.  In a study using human prostate 
carcinoma (PC-3) cells, flank xenografts in athymic nude mice receiving both the 
NOdonor DETA/NONOate and cisplatin showed a substantial reduction in tumor volume 
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progression versus the drugs individually [53].  Studies in tissue culture cells, including 
MCF-7 and HT29-dx showed that administration of various NO donors (SNAP, SNP and 
GSNO) partially reversed doxorubicin resistance [54, 55].  It has also been 
demonstrated that SNP radiosensitized pancreatic cells by enhancing the formation of 
DNA strand breaks and, by an unknown mechanism, radiosensitizes glioma cells [56, 
57].        
 There are several likely possibilities to this dual nature of NO in cancer 
therapeutics.  Evidence has suggested that the level of NO produced plays a role in the 
effects seen.  In general it has been shown that at low levels of NO (<100nM), cancer 
promoting pathways dominate, while at higher levels (>300nM), cytotoxic effects 
dominate [58].  Another factor that has to be taken into consideration is where in the cell 
the NO is being generated, and the fact that NO can have effects on the tumor cell and 
surrounding stromal cells resulting in different outcomes.  Thus external donors of NO 
may have very different effects than endogenously generated NO.  There are no 
definitive conclusions that can be made but there is enough evidence to warrant further 
consideration.  
Scope of the dissertation 
 An area of research that has yet to be extended to cancer therapeutics is the 
coupling state of NOS in cancer cells.  It has been established that tumor cells may 
originate and certainly thrive in inflammatory environments.  Experiments were 
approached from a new perspective of NOS dysregulation and being able to manipulate 
a tumor cells response to its inflammatory environment.  Studies in this dissertation 
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contributed to the elucidation of a novel role that NOS uncoupling plays in tumor cell 
proliferation and the potential mechanisms by which BH4 supplementation and NOS 
recoupling elicit antitumor effects.  In Chapter 2, a series of experiments conducted in 
various tissue culture cells, flank tumor xenografts and normal tissue determined that 
the BH4:BH2 ratio is significantly reduced in tumor cells, resulting in increased NOS 
uncoupling.   Several mechanisms including guanosine triphosphate cyclohydrolase I 
(GTP-CHI) overexpression, the rate-limiting enzyme in BH4 synthesis, and direct BH4 
supplementation were used to overcome the reduced BH4:BH2 ratio and were shown to 
restore NOS coupling.  By restoring NOS coupling we are able to manipulate the 
inflammatory environment in tumor cells and Chapter 3 examines the effects that 
increased NO produced through NOS recoupling has, with particular focus on signaling 
through the PKG and NFκB pathways.  In Chapter 4 the therapeutic potential of BH4 
supplementation was assessed by studying its effects on azoxymethane (AOM) induced 
colon cancer and Dextran sodium salt (DSS) induced colitis.  We conclude that 
restoration of NOS coupling in tumor cells plays a role in cellular proliferation and is a 
potentially viable therapeutic tool.  While we have established a role for PKG and NFκB 
in the antitumor effects of BH4 supplementation, experiments conducted in AOM 
induced colon cancers suggest that there may be other mechanisms involved. 
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Chapter 2 
NOS is uncoupled in tumor cells in vitro and in vivo 
 
NOS is uncoupled in inflammatory disease 
 Tetrahydrobiopterin is a necessary cofactor for the production of NO from NOS.  
Evidence has shown that NOS’s can generate O2
- under certain pathophysiological 
conditions and current research indicates that the level of BH4 is important in regulating 
the balance of O2
- and NO produced by NOS.  A BH4 molecule binds in the oxygenase 
domain of each NO synthase monomer resulting in two BH4 molecules in the active 
dimer.  In conditions where BH4 levels are low, electron transfer in the active site of the 
enzyme becomes uncoupled from L-arginine oxidation resulting in the production of O2
- 
instead of NO [59, 60].  The uncoupled enzyme therefore becomes a generator of 
ONOO-, which is produced rapidly by the reaction of O2
- with NO produced in the same 
area.  The reaction of NO with O2
- is six times faster than the reaction of O2
- with SOD 
so ONOO- formation is favored.  Figure 2.1 illustrates some of the cellular 
consequences of an uncoupled NOS.  Cell signaling shifts from sGC activation and S-
nitrosylation towards ONOO- and protein nitration.    
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In inflammatory diseases such as diabetes, hypertension and atherosclerosis 
loss of NO production is a common feature.  Until recently it was unclear how this was 
occurring as eNOS protein levels were still present at normal levels in the tissue 
endothelium.  Initial studies determined that under these inflammatory conditions there 
is an increase in ROS such as O2
-, H2O2, and hydroxyl radicals, that are able to react 
quickly with NO, reducing bioavailability.  More recent experiments showed that under 
certain inflammatory conditions the cofactor BH4 is limiting and that this results in 
reduced NO bioavailability [61].  Low levels of BH4 can be a result of the low levels of 
GTPCH-I, the rate-limiting enzyme in the production of BH4, or through direct oxidation 
of BH4 to BH2 in the face of enhanced ROS [62, 63].  Evidence has shown that NOS’s 
have an equal affinity for BH4 and BH2 but when BH2 is bound the NOS dimer is 
unstable and O2
- production dominates [64].  In this situation eNOS is uncoupled and 
not only a victim of the inflammatory environment, but also becomes responsible for 
enhancing that environment.      
Biopterin Metabolism 
 To further understand how BH4 is becoming limiting and how exogenous BH4 
exerts its effects we must have an understanding of biopterin metabolism.  BH4 was 
first discovered as a necessary cofactor of phenylalanine hydroxylases after it was 
determined that phenylketonuria, a disorder in converting phenylalanine to tyrosine, was 
caused by abnormal phenylalanine hydroxylase.  It was discovered shortly after that 
BH4 and its precursors were also required for tyrosine hydroxylase and neuronal 
tryptophan hydroxylase, the rate limiting steps in the production of dopamine and 
serotonin respectively [65].   
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 BH4 biosynthesis occurs via two mechanisms, the de novo synthesis and pterin 
salvage pathways.  Figure 2.2 shows the reactions involved in generating BH4.  On the 
right side is the de novo synthesis and is regulated by the availability of the rate limiting 
enzyme GTP-CH.  The salvage pathway involves conversion of SP to 7,8BH2 by SR 
and subsequent conversion to BH4 by DHFR.  Research has shown that BH4 does not 
accumulate to a great extent in tissue.  Cells take up BH4 from extracellular fluid, utilize 
it and expel its oxidized form and the process is repeated as necessary [66].     
 Studies aimed at raising intracellular BH4 have shown the salvage pathway to be 
responsible for the accumulation of BH4 in cells.  In a comparison of cellular uptake, SP 
was shown to elevate cellular BH4 concentration more effectively than BH4 and that the 
cellular increase was sensitive to methotrexate (MTX).  Since MTX is an in inhibitor of 
dihydrofolate reductase (DHFR) it was later determined that BH4 was actually 
converted to BH2 before entering the cell and being converted back to BH4 by DHFR 
[66]. 
 Hasegawa et al also showed that the BH4 accumulation with SP administration 
occurs more rapidly than with BH4 or BH2 as SP is readily transported into the cell 
where SR and DHFR catalyze the formation of BH4 and this BH4 is trapped in the cell 
due to the low permeability of the cell membrane.  It was for these reasons that SP was 
used in the bulk of our studies examining BH4 effects [67]. 
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MATERIALS AND METHODS 
Chemicals and Reagents 
 1.5mg, 60 day release pellets of 17β-estradiol were from Innovative Research of 
America (Sarasota, FL).  Pterin (#11.903), L-Sepiapterin (#11.225), Biopterin (#11.203), 
7,8 Dihydro-L-Biopterin (#11.206) , and (6R)-5,6,7,8-Tetrahydro-L-biopterin 
dihydrochloride (#11.212) were from Schircks Laboratories (Jona, Switzerland).  
Sodium Deoxycholate (D6750), Sodium Thiosulfate (S7026), Silver Nitrate (S1179), 
Potassium Carbonate (209619), 40% Formaldehyde (F8775), Ascorbic Acid (A5960), 
Potassium Iodide (P-4286), Nώ –Nitro-L-arginine (N5501), S-Nitrosoglutathione (N4148) 
and Iodine (20,777-2) were from Sigma Aldrich.  Hydrochloric Acid (A144-212), Sodium 
Hydroxide (SS255-1), HPLC grade Methanol (A452-4), HPLC grade Water (W5-4), 
DMSO (D128), HPLC grade Acetonitrile (26827-0040), Trifluoroacetic Acid and 
Perchloric Acid (A229) were purchased from Fisher Scientific.  Peroxynitrite (81565), 
Nitrotyrosine Affinity Sorbent (389549) and cGMP EIA kit (581021) were purchased 
from Cayman Chemical.  PBS (10010-023) RPMI 1640 (11875-093), Trypsin EDTA 
(15400-054), Penicillin Streptomycin (15240-062), Lipofectamine (50470) and Plus 
Reagent (10964-021) for transfection were purchased from Invitrogen.  Matrigel 
(356234) was purchased from BD Biosciences and dihydroethidium (D11347) was from 
Molecular Probes.  Human GTP-CHI was generously provided by Dr. Paul Graves 
(VCU Department of Radiation Oncology).  Nu/Nu mice were purchased from NCI.   
For animal studies involving treatment with SP, stock solutions of 0.8mg/ml in 
H2O were frozen at -20˚C.  When ready to use they were thawed and 1ml was diluted to 
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40ml in animal drinking H2O.  For tissue culture studies involving SP we used tissue 
culture medium as the solvent to make a 1mM stock solution which could then be 
diluted as necessary.  This solution was made fresh each time cells were to be treated.      
Cell culture 
 Fadu and A431 cells were from ATCC (Manassas, VA) and MCF-7 and MDA231 
were provided to us by Dr. David Gewirtz (VCU Department of Pharmacology and 
Toxicology).  All cell lines were grown as monolayers in RPMI 1640 supplemented with 
10% FBS and 50units/ml penicillin and streptomycin.  Cells were incubated at 37˚C in 
5% CO2.  Cells were passaged as necessary. 
Mouse tumor xenografts 
 For Fadu, A431 and MDA231 cells the method was the same.  Cells were 
trypsinized and counted.  1x106 cells in 50µl PBS was injected into each flank of 8 week 
old Nu-/ Nu- mice from NCI.  The mice for Fadu and A431 were male and we used 
female mice for the two breast tumor cell lines, MDA231 and MCF-7.  The latency 
period for the different cell types varied from two weeks for Fadu and A431 to up to two 
months for MDA.  To develop tumor xenografts for MCF-7 cells we had to use a 
different protocol.  MCF-7 cells are estrogen responsive and in order for these cells to 
develop into a tumor the animal had to be implanted with an estrogen pellet the day 
before cells were to be injected.  To do this we would make a small incision on the back 
of the mouse between the shoulder blades and insert a small 1.5mg 60 day release 
estrogen pellet under the skin before closing the incision and sealing it with super glue.  
The following day we would trypsinize and count cells.  2.5x106 cells in a 50µl mixture of 
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PBS and matrigel were then injected into the flank of 8 week old female Nu-/ Nu- mice.  
The latency period for tumor development was similar to MDA. 
 MMTV neu mice that developed spontaneous mammary tumors were provided 
by Dr. Paul Fisher (VCU Dept. of Human and Molecular Genetics).        
BH4 and BH2 measurements 
 A431, MCF-7 and MDA231 cells were plated at a density of 2x106 cells/100mm 
dish and were allowed to adhere overnight.   The next day cells would receive the 
indicated treatment and would then be placed back in the incubator for the duration of 
treatment.  When the cells were ready to be harvested the dishes were washed in ice 
cold 1x PBS three times.  After the final wash all PBS was removed and the cells were 
then lysed in 1ml of ice cold 0.1N HCl and placed in a 1.5ml microcentrifuge tube.  The 
samples would sit on ice for 20min and then would be centrifuged for 20min at 13,200 
RPM.  The samples were divided into aliquots and placed either into a -80˚C freezer or 
analyzed immediately for BH4 and BH2 content. 
 To analyze biopterin levels in tumors or other mouse tissue animals were 
euthanized with 20µl i.p. injection of euthasol.  Once the animal was sacrificed we 
harvested the desired tissue and snap froze it in liquid nitrogen.  The tissue was either 
placed in the -80˚C freezer or immediately homogenized in 10 volumes of 0.1N HCl with 
a pestle and mortar kept on ice.  The resulting tissue homogenate was centrifuged for 
20min at max speed and the supernatant would be stored in aliquots at -80˚C.   
 The protocol for HPLC analysis was adapted from Woolfe et al (1983).  Three 
solutions were needed in order to perform the acid/alkaline oxidation:  2%I2/3%KI in 
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0.1N HCl, 2%I2/3%KI in 0.2N NaOH, and 2.5% Ascorbate in 0.4N HClO4
-.  100µl of 
sample was incubated with 62.5µl of the HCl solution in one tube while another 100µl of 
sample was incubated with the NaOH solution for 1h at room temperature in the dark.  
After 1h, .5vol of the ascorbate solution was added to each tube and the samples 
centrifuged at 12,000 RPM for 10min.  50µl of the resulting supernatant from each 
sample was separated by HPLC on a Whatman RTF partisphere column using 5% 
methanol as the mobile phase at a flow rate of 1.0ml/min and fluorescent detection at 
350/450nm.  
 To determine the BH4:BH2 ratio we compared the acidic and alkaline 
chromatograms for each sample.  Under acidic conditions both BH4 and BH2 were 
converted to biopterin and eluted in one peak, while under alkaline conditions BH4 was 
converted to pterin and now eluted in a different peak.  Comparing the areas under the 
curve we were then able to obtain the ratio of the two.   
 Determining cellular cGMP content 
 To make these measurements we took advantage of the fact that samples were 
to be harvested in 0.1N HCl, which allowed us to use some of the supernatant aliquots 
from the samples for BH4:BH2 analysis.  We purchased a cGMP EIA kit from Cayman 
Chemical and followed the directions as described in the manual.  The samples were 
not acetylated. 
Superoxide quantification 
 We can measure O2
- production in cells by measuring the interaction of O2
- with 
exogenous dihydroethidium to form 2-hydroxyethidium.  A protocol was adapted from 
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Zielonka et al to determine cellular concentrations of O2
- in tissue culture [68].  1x106 
cells were plated in 60mm dishes and placed in the incubator overnight to allow cells to 
adhere.  Dishes were treated with SP according to the desired concentration and 
duration of incubation.  30 min prior to harvesting the cells, culture medium containing 
10µM HE (5µl of 20mM HE in DMSO per 10ml of medium) was added to each dish.  At 
this point three 1.5ml tubes for each sample were prepared:  one empty tube to store an 
aliquot for protein determination, the second tube has 100µl of 0.2M HClO4 in methanol 
and the third tube has 100µl of 1M phosphate buffer pH 2.6.  To stop the reaction, 
medium was removed and the cells were washed with ice-cold 1x PBS three times.  In 
the final wash 1ml of ice cold PBS was added to each dish and the cells scraped into a 
1.5ml eppendorf tube.  The cells were concentrated by centrifuging for 5 min at 1,000 
RPM at 4˚C.  The cells were lysed by adding 150µl of ice-cold PBS containing 0.1% of 
Triton X-100 to the cell pellet and trituration by drawing the mixture in and out of an 
insulin syringe ten times.  The resulting lysate was clarified by centrifugation:  20 min x 
12,000 RPM at 4˚C.  To isolate the product, 2-hydroxyethidium, 100µl of the lysate 
supernatant was transferred into the tube containing 0.2M HClO4 in methanol and 
vortexed for 10 seconds.  The tubes were placed on ice for 1.5h to allow protein 
precipitation.  Following this incubation, the protein precipitate was removed by 
centrifugation:  45 min x 13,200 RPM at 4˚C.  100µl of the resulting supernatant was 
added to the tube containing 1M phosphate buffer pH 2.6 and vortexed for 5 seconds.  
After a second centrifugation, 25 min x 13,200 at 4˚C, the supernatants were loaded 
into HPLC vials and kept on ice until placed into the HPLC. 
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 Once samples were in the vials they were placed in the sample tray of the HPLC 
which was preset to 4˚C.  We used a Whatman RTF partisphere C18 column to separate 
the samples.  The column was equilibrated with 10% CH3CN in water containing 0.1% 
TFA for 15 min before samples were injected.  50µl of sample was loaded onto the 
column and was separated by gradient elution using water containing 0.1% TFA (mobile 
phase A) and 99.9% CH3CN with 0.1% TFA (mobile phase B) at a flow rate of 
0.5ml/min.  Table 1 is taken from Zielonka et al. and shows the gradient used for 
fluorescence detection of 2-hydroxyethidium at 510nm (excitation) and 595nm 
(emission).  To determine sample concentration compare to standard curve produced 
from by injecting serially diluted standards.     
Analysis of nitrated and S-nitrosylated of proteins 
 Cells were plated at a density of 2x106/150mm dish.  Cells were allowed to grow 
to 70% confluent and were then treated with SP for 6 hours or were left untreated.  For 
nitration, dishes were washed 3x with ice cold 1X PBS and then cells were lysed in 
1.0ml of ice cold buffer containing 50mM Tris pH 7.4, 150mM NaCl, and 1% NP-40.  
Lysates were cleared by centrifugation at 13,200 RPM for 20 min at 4˚C.  As a positive 
control lysates were treated with 6µl of 150mM ONOO- by adding a droplet to the cap of 
the microcentrifuge tube and vortexing for 10s (not added directly to the tube due to the 
short half-life).  Samples were then immunoprecipitated overnight at 4˚C with 10µl of 
Nitrotyrosine affinity sorbent.  The samples were washed the following day twice with 
ice cold lysis buffer and once with ice cold 1X PBS.  After removal of as much PBS as 
possible, 40µl of Llaemmli sample buffer was added and the samples were boiled for 
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5min.  Samples were loaded and the proteins separated on a 10% SDS-Page gel.  
Proteins were visualized by silver stain. 
 To analyze cells for protein s-nitrosylation we plated and treated the cells in the 
same manner as for nitration.  When the time came to lyse the cells, they were lysed in 
the dark in 450µl of RIPA buffer (50mM Hepes, 150mM NaCl, 1% Trition X-100, 0.1% 
SDS and 1% Sodium Deoxycholate).  As a positive control one of the lysates was 
treated with GSNO.  The biotin switch method was used for the detection of s-
nitrosylated proteins.  The beads were washed three times in wash buffer and the 
beads were boiled for 5min in laemmli sample buffer.  Samples were then loaded and 
the proteins separated on a 10% SDS-Page gel.  Proteins were visualized by silver 
stain. 
Biotin Switch Method 
 This method was used to determine Cys s-nitrosylation.  For total cellular s-
nitrosylation, cells were grown to 80% confluent and then harvested.  For analysis of a 
specific protein it was typically overexpressed.  In MCF-7 cells, 1.2x106 cells were 
plated and allowed to adhere overnight.  The plasmid DNA encoding the protein(s) of 
interest was introduced the following day using Lipofectamine/Plus transfection 
reagents.  48 hours after transfection cells were treated and cell lysates were prepared 
at the designated time points in RIPA buffer.  The resulting cell lysate was centrifuged 
for 5 min and the supernatant was mixed with blocking buffer (250mM Hepes pH 7.7, 
1mM EDTA, 0.1mM neocuproine, 2.5% SDS, 20mM MMTS ) to block all free 
sulfhydryls.  The sample was then mixed with acetone to precipitate the proteins to 
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remove MMTS.  The preceding steps are done under conditions of low light as to not 
create additional reactive Cys from exposure to UV.  The pellet is resuspended in Hens 
buffer (25mM Hepes 7.7, 0.1 mM EDTA, 10µM neocuproine, 1% SDS) to which is 
added biotin-HPDP and ascorbate to a final concentration of 1mM.  Samples incubate 
for 1 hour at room temperature.  Proteins are again precipitated with acetone to remove 
excess biotin.  Proteins are resuspended in neutralization buffer (20mM Hepes, 100 mM 
NaCl, 1mM EDTA, 0.5% Triton X-100)  and the biotin labeled proteins are purified on 
streptavidin-agarose beads overnight, washed the following day with wash buffer 
(neutralization buffer with 600mM NaCl) and then eluted in sample buffer containing β-
mercaptoethanol.  The samples were then resolved by SDS-Page.  Western blots are 
probed with streptavidin for total s-nitrosylation or with antibodies for specific proteins.   
Silver Stain Protocol 
  The gel is fixed 10% methanol and 10% acetic acid for 30min and subsequently 
washed four times in water, at least 5min per wash.  Gels are incubated in sodium 
thiosulfate (1 pellet per 500ml of water) for 90 seconds exactly saving 20ml of this 
solution for use later.  The gelis then quickly washed three times three with water (fill 
dish then dump, repeat).  A silver nitrate solution (0.9g of silver nitrate in 500ml of 
water) is then added and the gel is stained for 10min.  The gel should turn slightly 
yellow.  After 10min, the gel is washed three times quickly with water.  Developer 
solution (10g of potassium carbonate, 20ml of sodium thiosulfate from above, and 250µl 
of 40% formaldehyde in 500ml of water) is added and staining of the gel is followed.  
When the staining reaches a satisfactory level, the reaction is stopped by the addition of 
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destain (10% methanol and 5% acetic acid) and the gel is washed two to three times in 
water.          
RESULTS 
NOS is uncoupled in tumor cells 
 The consequences of NOS dysregulation have been discussed thoroughly in the 
previous sections.  Here we examined whether or not tumor cells have an uncoupled 
NOS in tissue culture cells and mouse tumor models.  We were able to do this through 
examining the hallmarks of NOS uncoupling:  decreased BH4:BH2 compared to normal 
tissue and increased O2
- in lieu of NO leading to increased Tyr nitration.  Preliminary 
experiments focused on the ability of ONOO- to oxidize BH4 to BH2 as this is a 
mechanism by which cellular BH4 levels are manipulated during inflammation.  To 
accomplish this we harvested the kidney, heart and colon of several C57BL/6 mice and 
treated a portion of the resulting organ homogenate with 10µl of 140µM ONOO- (final 
concentration 1.4 µM).  The amount of BH4 and BH2 in the tissues was measured by 
acidic/alkaline oxidation to either biopterin or pterin using HPLC as described.  Figure 
2.3 shows a decrease in the BH4:BH2 ratio from 9.1:1 in normal tissue to 1.7:1 in tissue 
treated with ONOO- (only the data from the colon are shown but the other tissues were 
similar).   This data demonstrates that a major product of an inflammatory environment, 
ONOO-, is able to oxidize BH4 to BH2, which is consistent with our model of BH4 in the 
tumor microenvironment, and that we are able to measure this change 
 To determine the extent of NOS uncoupling in tumor cells we compared the 
BH4:BH2 ratios of normal tissues to several cell lines of interest, both in vitro and 
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 in vivo.  Tumor cells were evaluated in several different ways to assess BH4:BH2.  We 
grew them as a monolayer in tissue culture dishes, as flank xenografts in mice, or we 
analyzed spontaneously derived tumors.  Figure 2.4 shows that in each tumor cell line 
we tested, whether in tissue culture or as a tumor, the BH4:BH2 ratio was significantly 
lower than in normal tissue, with MCF-7 cells being the most aberrant.  With ratios in 
some of these cell lines significantly below 1, the main activity of NOS in these cells is 
as a peroxynitrite synthase.  If we look again at Figure 2.2, we see several approaches 
(the circled items) that have the potential to elevate cellular BH4 and we wanted to 
determine whether these compounds could be effective in elevating BH4:BH2 in the 
tumor cell lines we were investigating.  We can take the genetic approach and 
overexpress GTP-CHI, the rate-limiting enzyme in BH4 biosynthesis.  We can use SP 
exogenously, which is taken up by cells and converted to BH4 through SR and DHFR, 
or we can give direct administration of BH4.  Figure 2.4 shows the effect of adding SP 
or BH4 to the drinking water of mice or treating tissue culture cells with SP, BH4 or 
overexpressing GTP-CHI.  Animals were treated for 24 hours and tissue culture cells 
were incubated for 6 hours.  The BH4:BH2 ratio is significantly increased with each 
compound with SP having the greatest effect in both tissue culture and mice.  In our 
studies as well as by others it has been shown that the most effective route for 
enhancing the BH4:BH2 ratio is through exogenous SP, which is why it is the compound 
of choice in the bulk of our studies [66]. 
SP enhances NOS coupling in tumor cells   
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Figure 2.4.  BH4:BH2 ratio.  BH4:BH2 ratio was measured by HPLC in normal tissue 
from Nu
-
/Nu
-
 mice, various tissue culture cells and flank tumor xenografts from the 
indicated cell.  In all cases the ratio of BH4:BH2 is lower in tumor tissue and we are 
able to elevate it with exogenous agents that generate BH4 in cells. N=3 and data is 
reported as the mean +/- SEM. 
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We determined that NOS is uncoupled in a variety of tumor cells and that we are 
able to manipulate the BH4:BH2 ratio in these cells.  To assess whether or not 
enhancing BH4:BH2 had an actual effect on the product from the oxidation of L-Arginine 
we monitored two key cellular components: cGMP formation and O2
- generation.  cGMP 
is formed from the interaction of NO with its main target in cells, sGC.  In our 
experiments we used cGMP formation as an indirect method for measuring NO 
generation.  To assess O2
- generation we monitored the oxidation of diyhdroethidium to 
either hydroxy or dihydroxyethidium.  The product formed here has been shown to be 
due to the interaction of dihydroethidium with O2
- as it was not formed by reaction with 
other oxidants (H2O2 or ONOO
-) [66].   To gain an understanding of the time required for 
SP to recouple NOS in tumor cells, MCF-7 cells were treated with 20µM SP and 
harvested at various time points post treatment followed by determination of the 
BH4:BH2: ratio (Figure 2.5).  What we found was that the ratio began to elevate around 
3 hours with a maximum level achieved at 6hrs and maintained until roughly 18hrs.  We 
had now determined the window in which all future experiments would be conducted, as 
maximum BH4:BH2 ratio directly correlates to maximum NOS coupling. 
Experiments that followed determined if during this time period there was 
enhanced cGMP formation.  Earlier studies used a concentration of SP from the 
literature that was shown to be effective in mediating aberrant NO production from NOS, 
but we decided to examine cGMP formation over a range of concentrations.  In Figure 
2.6 we show that 6 hours after treatment cGMP increased in a concentration dependent 
manner in both MCF-7 and MDA 231 cells (only the data for MCF-7 cells is shown as  
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the results were extremely similar).  We also measured the effect of SP on cGMP in 
flank tumor xenografts of these cells and found that after 48 hours of SP in the drinking 
water there was a significant increase in cGMP.  We decided to wait for 48 hours to 
harvest the flank tumor due to the animals receiving SP via drinking water to make sure 
that they had time to ingest it and reach a steady level (Figure 2.6).  We pretreated cells 
with the non-selective NOS inhibitor, LNNA (200nM), to confirm the role of NOS in the 
changes of cGMP with exogenous SP.  The rationale is that by enhancing NOS 
coupling, NO production will increase and since sGC is one of the main interactions with 
NO, the level of cGMP should increase.  Pretreatment of cells resulted in nearly 
complete reversal of the effects SP had, confirming that SP acts by enhancing the 
BH4:BH2 ratio thereby stimulating NOS coupling and NO generation.    
  To assess cellular O2
- production from NOS we used the same doses and time 
point (6hr) to harvest cells.   Figure 2.7 shows a dose dependent decrease in O2
- from 
NOS in MCF7 and MDA231 cells.  Since NOS uncoupling is generating some of this O2
- 
the NOS inhibitor L-NNA treatment should block the portion that is being generated by 
NOS and we do see O2
- blocked in the presence of 200nM L-NNA.    
SP changes the balance of signaling from nitration to s-nitrosylation 
Now that we were seeing more NOS coupling we wanted to determine if there 
was an overall decrease in total cellular Tyr nitration and if that led to a concomitant 
increase in Cys s-nitrosylation.  Figure 2.8 shows that treating cells with 20µM SP for 6h  
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results in decreased overall protein Tyr nitration and that 20µM SP enhanced formation 
of S-nitrosothiols in a variety of proteins.  Without a specific target in mind we decided to 
examine overall nitration and S-nitrosylation by purifying the proteins based on the post 
translational modification and then separating them on a gel and silver staining the gel. 
This only showed us modifications on very abundant proteins, but was sufficient to 
establish the trend of moving from nitration to S-nitrosylation. 
DISCUSSION 
In view of the importance of BH4 in NOS function and its known sensitivity to 
oxidative stress and NOS’s role in redox signaling we hypothesized that: (i) BH4 
depletion in tumor cells contributes to promotion of the inflammatory tumor micro 
environment through NOS uncoupling and, (ii) that exogenous BH4 would be effective 
in reducing this.  Due to BH4 being a requirement for NOS production of NO and that 
BH2 has an equal affinity for NOS, we examined the BH4:BH2 ratio in tumor cells and 
found that they were reduced when compared to normal tissues resulting in O2
- 
production from NOS in lieu of NO.  Exogenous BH4 raised intracellular BH4:BH2 ratios 
increasing NOS coupling as measured by increased cGMP formation and decreased 
O2
- generation.  Figure 2.9 summarizes what we have shown experimentally.     
A fully coupled NOS is the result of a stable homodimer with BH4 as the cofactor.  
NOS dimers that are formed with BH4 have been demonstrated to be stable in 2% SDS 
at temperatures below 30 C while NOS dimers without BH4 as the cofactor are not [69]. 
The extent to which exogenous SP stabilizes the NOS dimer could be measured and  
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would provide additional evidence of fully recoupling NOS activity, but we feel the 
evidence clearly demonstrates NOS uncoupling and manipulation of uncoupling by SP. 
The extent to which O2
- decreased in the presence of SP was surprising and may 
be explained by free radical scavenging by NO. NO produced from the coupled enzyme 
can scavenge O2
- from mitochondrial respiration or NOX activity to form ONOO-.  The 
formation of hydroxyethidium is a product specific to oxidation by O2
- and not ONOO- so 
NO scavenging would reduce the amount of O2
- detected.  Free radical scavenging by 
NO may also explain the difference between O2
- produced in the presence of SP and 
after treatment with L-NNA. We would expect NOS inhibition to limit O2
- production to 
the extent that SP did as we are eliminating the same sources of O2
-.  We therefore 
attribute some of the reduction of O2
- in the presence of SP to scavenging by the 
increased NO production from a coupled NOS reacting with cellular O2
-. 
We demonstrated a trend that overall cellular nitration goes down and S-
nitrosylation goes up, but that may not always be the case.  By enhancing NOS 
coupling we increase the amount of NO generated in cells, increasing the diffusion 
distance of NO.  It is possible that individual proteins may be nitrated to a greater 
extent, especially those proteins associated with mitochondria and NADPH oxidases.   
Potential limitations to these experiments are that the tumor xenografts are 
generated in immune deficient mice.  Given that the innate immune system contributes 
to tumor progression through mechanisms discussed earlier and that response is 
partially mediated by NOS there is a possibility that the extent of BH4 depletion may 
have been greater as there would have been an active immune response.  This would 
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lead to a higher degree of NOS uncoupling in the immunocompetent animals.  There is 
also a key piece of information that is undetermined by these studies.  Are the effects of 
exogenous BH4 in animals due to effects on the surrounding stromal cells reducing the 
inflammatory environment, on the tumor cells themselves or both?    
It was initially demonstrated that eNOS effects on tumorigenesis were due to 
activity in endothelial cells, but as discussed in the introduction, eNOS activity in tumor 
cells plays a vital role in maintaining tumor through redox activation of key signaling 
proteins [70].   Lim et al described how tumor maintenance is mediated by eNOS and 
demonstrated that S-nitrosylation of Ras proteins was critical for PI3K-AKT regulation of 
tumor cell proliferation [71].  When they inhibited eNOS they blocked tumor initiation 
and maintenance.  Their experiments did not determine the level of total S-nitrosylation 
of eNOS in their cells and given what we know about this post-translational modification 
it is highly unlikely that just S-nitrosylation is responsible for the oncogenic effects they 
demonstrated.  We discussed earlier that in an inflammatory environment proteins can 
be modified by nitration, S-nitrosylation and S-oxidation.  Given that NOS is intimately 
involved in redox signaling, we believe that the contribution of an uncoupled NOS 
contributes greatly to what they have shown.  Our findings underscore the importance 
that a decreased BH4:BH2 ratio may have in tumor cells.  We are able to manipulate 
how tumor cells respond to an inflammatory insult through exogenous BH4 to maintain 
NOS coupling.  These findings also point to a need for further understanding of the role 
of NOS uncoupling in the redox state in tumor cells.   
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Chapter 3:  
 Modulation of Critical Signaling Pathways in Breast Cancer Cells 
 
INTRODUCTION 
 In chapter 2 we clearly demonstrated that NOS is uncoupled in tumor cells and 
that the extent of uncoupling can be manipulated by exogenous compounds.  The focus 
of this chapter is the investigation of the consequences of NOS recoupling and the 
signaling pathways manipulated through this process, with particular focus on several of 
the constitutively active pathways that play a role in breast cancer cells:  β-catenin, 
NFκB and STAT3.  That we altered cellular ROS/RNS, the expectation is that signaling 
through redox sensitive proteins will be altered.  Both NF B and STAT3 are redox 
regulated.  The role of PKG is thoroughly investigated as increasing NO results in 
increased cGMP which should lead to an active PKG.  Figure 3.1 is a schematic of the 
pathways being investigated and how we believed the recoupling of NOS would affect 
them.   
cGMP Dependent Protein Kinases and Their Role in Cancer 
 As discussed in the introduction the main target for NO in cells and the target 
with the highest affinity is the heme binding domain of sGC.  This stimulates a rapid  
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increase in cGMP and activation of cGMP dependent PKG, a serine/threonine kinase.  
There are two types of PKG encoded by different genes, types I and II.  Type I can be 
alternatively spliced to form PKGIα and PKGIβ that differ only in the amino-terminal 89 
and 104 residues and their affinity for cGMP (α is ten times more sensitive to cGMP 
than β).  PKGI is usually associated with the cytoplasm whereas PKGII, with a 
myristylated N terminus, is generally associated with the plasma membrane.  PKGI has 
been studied extensively while the function of PKGII remains more a mystery.  PKGII 
has been shown to be expressed highly in the intestinal mucosa and in the brain. In the 
intestine it has been demonstrated to play a role in Cl- and Na+ transport [72]. Although 
PKGI distribution appears to be ubiquitous, expression levels vary in different tissues.   
It has been detected in high concentrations in VSMC’s and platelets and lower 
concentrations in vascular endothelium and cardiomyocytes.  A major function of PKG 
as a vasoregulator was described previously, but PKG is known to have many other 
functions.  Evidence for the activity of PKG has been demonstrated in modulating the 
activity of stress and growth regulated MAPK, p38 and ERK respectively.  PKG directly 
phosphorylates p38 leading to ATF-2 dependent gene expression and phosphorylates 
Raf uncoupling Ras-Raf interaction and preventing ERK1/2 activation [73, 74].  PKG 
regulates the activity of c-fos, JunB, p21, NFκB and has been shown to directly regulate 
the CRE sites of the cyclin D1 promoter [75, 76].   
 Much of the evidence for the role of PKG in tumor cells comes from exogenous 
expression as there is considerable data showing loss of endogenous PKG expression 
in cultured cells [77].  Not only do tumor cells lose PKG as they are passaged, but a 
comprehensive examination using cDNA arrays showed that PKGI expression was 
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found to decrease in tumor cells compared with normal cells [78].  Some tumor cells 
have lost PKG entirely and this appears to be a mechanism by which the cells avoid 
apoptosis.  To study PKG function in tumor cells, IB Weinstein’s group constructed 
several PKG mutants and determined that when introduced into SW480 colon cancer 
cells, PKGIβ inhibited colony formation and induced apoptosis.  If they overexpressed 
the dominant negative mutant, the effect was lost [79].     
An alternative approach to stimulating cGMP production through exogenous 
activators of sGC is through inhibition of PDE’s that break down cGMP.  It has been 
shown that metastatic breast, colon and lung cancers have increased levels of PDE 2 
and/or PDE 5 compared to normal tissue [80].  Exisulind , sulindac sulfone (a metabolite 
of the NSAID sulindac), has been shown to have proapoptotic effects in SW480 and 
HT29 cells by inhibiting PDE’s leading to elevated cGMP [81, 82].    
Anti-angiogenic effects of PKG have also been demonstrated in SW620 tumor 
xenografts.  SW620 cells expressing an exogenous PKG produced smaller, more 
apoptotic tumors and further examination determined that the parental cell line led to 
tumors that were more highly vascularized compared to those overexpressing PKG.  It 
was observed that VEGF expression in the SW620 cells overexpressing PKG was 
significantly reduced compared to “normal” SW620 cells [83].   
 The exact mechanism of how PKG leads to growth arrest and apoptosis is still 
under investigation.  Several researchers have examined this apoptotic effect of PKG 
and have demonstrated that it can occur through sustained activation of JNK1, induction 
of p21/waf1, a decrease in β-catenin, a decrease in cyclin D1, and through activation of 
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caspases [79, 84-86].  Taken together, the above data suggest that by increasing PKG 
activity through recoupling of NOS, tumor cells can be driven in an anti-proliferative 
direction.   
-catenin 
 β-catenin plays a significant role in both normal mammary development and in 
tumorigenesis.  β-catenin interacts with cadherins at the plasma membrane in cell-cell 
adhesion complexes which function to maintain epithelial integrity.  Its central role in this 
complex allows it to regulate cell growth and adhesion between cells.  The location of β-
catenin within a cell and its expression are often abnormal in breast tumors.  Increased 
cytoplasmic and nuclear β-catenin levels in breast tumors correlate with poor prognosis 
and are seen in about 40% of breast tumors [87-90].   
 The most well defined pathway for β-catenin stabilization is through canonical 
Wnt signaling (Figure 3.2).  Wnt ligands prevent the destruction of β-catenin resulting in 
cytoplasmic accumulation and subsequent translocation into the nucleus where it is 
recruited by and associates with TCF/Lef DNA binding proteins (group of transcription 
factors involved in Wnt signaling) resulting in cell-context specific gene expression, to 
include c-Myc, cyclin D1, and c-Jun [91].   
 Research has shown that  retroviral insertion of active Wnt-1 was sufficient to 
induce mammary tumors and follow up studies have demonstrated similar results in 
transgenic animals expressing Wnt1, Wnt3 and Wnt10b [92-94].  Several human breast 
tumor cell lines and patient tumor samples have been found to over express Wnt ligand 
and dishevelled (a phosphoprotein downstream of Wnt receptors) has been shown to  
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be upregulated in up to half of breast cancers, both promoting β-catenin signaling [95-
98].   
β-catenin regulation by PKG has been studied extensively in colon tumorigenesis 
as members of the Wnt family control renewal of the luminal epithelium at the crypt 
base [99].   APC is a tumor suppressor gene that is often mutated in colon cancer.  As 
shown in figure 3.2, β-catenin associates with APC in a complex with GSK3β and 
phosphorylation of β-catenin by GSK3β leads to its degradation, regulating cellular 
proliferation.  Research has demonstrated that many colorectal tumors contain an APC 
that is unable to bind β-catenin, leading to enhanced β-catenin signaling even in the 
absence of Wnt [100]. 
Downregulation of β-catenin signaling by PKG has been studied extensively in 
colon tumorigenesis; however inhibition of its signaling plays a role in limiting tumor 
growth in other cancers as well.  Induction of p21/waf1 in gastric carcinomas was due to 
loss of β-catenin signaling and resulted in apoptosis [101].  In MDA231 xenografts, the 
inhibitory effect of naringin was found to occur through modulation of p21/waf1 and 
suvrvivin by inactivation of β-catenin [102]. 
Given that β-catenin plays a role in mammary tumorigenesis and due to the 
possibility of increasing a known modulator of its signaling, PKG, we decided to 
examine the effects on β-catenin signaling in breast tumor cells after treatment with SP. 
Nuclear Factor Kappa B 
 The NFκB family of transcription factors are mediators of the immune and 
inflammatory response in cells as a result of injury or infection.  NFκB exists as homo or 
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heterodimers of five family members including p50/p105, p52/p100, c-Rel, RelB, and 
p65 (RelA), and in unstimulated cells these proteins are sequestered in the cytosol by 
their inhibitor proteins, the IκB proteins.  The classical pathway for NFκB activation 
involves activation of IKK’s through ligand binding to Toll Like Receptors and cytokine 
receptors such as TNFR.  Active IKK’s phosphorylate IκB causing its dissociation from 
the NFκB dimer resulting in translocation of the dimer to the nucleus and transcription of 
corresponding genes.  The physiological response in the cell due to activation of NFκB 
can be any of an inflammatory response, an immune response, a cell survival response 
or a cell proliferation response. 
NFκB plays a major role in the interaction between the immune system and 
cancer cells and its actions help to shape the tumor microenvironment.  This 
environment is rich in inflammatory cells and ROS [103].  An area of great interest to 
our lab has been the regulation of NFκB by ROS/RNS.  The activation of NFκB can lead 
to increased NO production in cells through increased eNOS transcription and through 
stimulation of NOSII [104].   NO, in turn, has been shown to regulate NFκB activity in a 
negative feedback manner by directly modulating the activity of some family members 
resulting in the inhibition of NFκB signaling.  Tyrosine nitration of p65 has been shown 
to inactivate NFκB signaling in HEK293 cells [105].  S-nitrosylation of p65 inhibits NFκB 
dependent gene transcription in cytokine stimulated A549 cells [106].  Under conditions 
of shear stress, the p50 subunit has been shown to be s-nitrosylated inhibiting the 
binding of the p65/p50 heterodimer to DNA.  NO-donating aspirin in colon cancer cells 
s-nitrosylates the p65 subunit and this results in decreased binding of the heterodimer 
to DNA as well [49].  This data further implicates NO in modulating the inflammatory 
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state of the cell.  Our lab demonstrated that low level NO production results in tyrosine 
nitration of IκBα results in dissociation from the NFκB dimer resulting in translocation of 
the p65/p50 complex into the nucleus [25].  NFκB is also regulated by a variety of post 
translational modifications (e.g. phosphorylation and acetylation) that regulate its 
nuclear localization, DNA binding, oligomerization, interactions with coactivators and 
corepressors, that may also be ROS sensitive [107]. 
Evidence has shown that many breast tumors express a constitutively active 
NFκB, leading to enhanced tumor progression via activation of pro-survival pathways, 
angiogenesis pathways, and cell proliferative pathways, which have been shown to 
occur through several mechanisms, including upregulation of Bcl-2 and activation of 
MAP kinases.  Several NO donating drugs (nitric oxide-donating aspirin, NO-ASA) have 
shown positive results as cancer prevention agents.  The mechanism by which this 
occurs has been shown to be through S-nitrosylation of proteins, including p53, p65 and 
β-catenin in HCT116 cells.  The importance of NFκB as a therapeutic target in cancer is 
further appreciated by the fact that current chemotherapeutics and radiotherapy can 
lead to its activation.  It has therefore been postulated that this enhanced NFκB activity 
contributes to the development of resistance to these modes of treatment.  In light of 
this there has been substantial research aimed at the use of NFκB inhibitors as 
sensitizers for therapy.  Bortezomib is an inhibitor of IκB degradation and therefore 
blocks NFκB activity.  This drug showed great promise in pre-clinical studies as an 
adjuvant to other chemotherapeutics, but turned out to be ineffective and caused 
significant toxicities [108].  Off target effects can be a major drawback to NFκB targeted 
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therapies as they are involved in a wide array of signaling pathways.  Here we 
examined NFκB activity from the novel perspective of NOS dysregulation.   
STAT3 
 Signal Transducers and Activators of Transcription (STATs) are a family of 
cytoplasmic proteins that participate in normal cellular responses to cytokines and 
growth factors.  When receptors such as EGFR, PDGFR, fibroblast growth factor 
receptor (FGFR), and granulocyte colony-stimulating factor receptor (GCSFR) are 
activated it sets off a tyrosine phosphorylation cascade.  There are several ways in 
which this can occur.  Receptors like EGFR, once bound by ligand, dimerize and auto-
phosphorylate tyrosine residues which other proteins, like STATs, are able to interact 
with through their phophotyrosine binding SH2 domains.  Another well characterized 
mode of STAT activation involves the recruitment of Janus kinases (JAKs) to activated 
receptors.  JAKs, which have tyrosine kinase activity bind to the activated receptor and 
phosphorylate tyrosine residues on the receptor creating sites for interaction with 
STATs SH2 domains.  The recruitment of STAT to the receptor and subsequent 
phosphorylation on Tyr 705 results in STAT dimerization and translocation to the 
nucleus stimulating transcription of the responsive genes.  Recently however, it has 
been shown that unphosphorylated STAT3 is still capable of dimerization and 
transcriptional activities[109].  STAT3 is constitutively activated in approximately half of 
primary breast tumors where it plays important roles in survival, drug resistance, and 
angiogenesis.   Constitutive activation of STAT3 has been demonstrated to occur 
through hyperactivation of JAK’s and Src kinase (Burke WM 2001).  Previous studies 
have demonstrated that downregulation of STAT3 results in decreased tumorigenicity in 
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several breast cancer cell lines in vitro and in vivo [110, 111].  Introduction of anti-sense 
or dominant negative STAT3 leads to apoptosis in several human tumor cell lines and 
knockdown of STAT3 by RNA interference inhibits the induction of breast tumors in 
immunocompetent mice [112].  Identification of STAT3 as being constitutively active led 
to a push for the development of small molecule inhibitors which have exhibited anti-
tumor potential.  FLLL31 and FLLL32 bind selectively to JAK2 and the STAT3 SH2 
domain and have been shown to be effective inhibitors of STAT3 phosphorylation and 
DNA binding activity [22]. 
 Given that STAT3 is upregulated in many breast tumors, blockade of STAT3 
signaling results in decreased tumorigenesis, and that activation of STAT3 comes from 
receptor tyrsosine kinases that have been shown to be regulated by ROS, investigation 
of STAT3 after treatment of breast tumor cells with SP seemed logical.    
MATERIALS AND METHODS 
Chemicals and Reagents 
KT5823 (10010965) and ODQ (81410) were purchased from Cayman Chemical.   
NAC (A1824), 8-Br-cGMP (B1381), Trypsin (T9201), Collagenase (C0130), and DNase 
(D4527) was from Sigma.  Propidium Iodide (51-66211E) was from BD Pharmingen 
(Franklin Lakes, NJ). The luciferase based reporter construct of NFκB (pNFκB–Luc) 
was purchased from Clontech (Mountain View, CA).   The TCF/LEF reporter construct 
was from Addgene (plasmid 12456) and was provided to them by Randal Moon.  NPH4 
(11.309) was purchased from Schircks Labs. 1% Casein in TBS was from BioRad (161-
0782).  LucLite luciferase reporter gene assay kit was from Perkin Elmer (Waltham, 
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MA).  WST-1 (05015944001) reagent was from Roche (Indianapolis, IN).  STAT3 IRDye 
700 labeled oligonucleotides (829-07922) and Odyssey EMSA Buffer Kit (829-07910) 
were form Li-Cor (Lincoln, NE).  10X TBE (EC-860) was purchased from National 
Diagnostics (Atlanta, GA).  
The following primary antibodies were used:  anti-Bcl-2 (sc-7382), pVASP (sc-
23507) and actin (sc-1616) were from Santa Cruz Biotechnology (Dallas, TX).  Anti-p65 
(4764), anti-p50 (3035), anti-p21 (2947), anti-cyclin D1 (2978), anti-JNK1/SAPK (4668), 
anti-pGSK3β (9323) and anti-Stat3 (9131) were from Cell Signaling Technology 
(Danvers, MA). Ant- c-Myc EZview affinity gel (E6654) was from Sigma Aldrich (St 
Louis, MO).  Anti-PKG (KAP-PK002) was from Stressgen (Ann Arbor, MI).  Anti-
Nitrotyrosine (06-284) was from Millipore Corp (Billerica, MA).  Anti-β-Catenin (610153) 
was from BD Tansduction Laboratories (Franklin Lakes, NJ).  The secondary antibodies 
used were IR conjugated and designed for use on the Li-Cor Odyssey Infrared Imager:  
anti-rabbit 800 (611-132-003), and anti-goat 700 (605-730-002), were from Rockland 
Immunochemical (Gilbertsville, PA).   
Luciferase Reporter Gene Assay 
 NFκB:  MCF-7 cells were plated at a density of 1.2x106 cells/60mm dish and the 
cells were allowed to incubate overnight to adhere.  We then transfected the cells with 
NFκB-Luc or according to the Lipofectamine/Plus protocol from Invitrogen.  We then 
treated the cells for 4 hours with SP after which the old medium containing the SP was 
removed and new medium was added.   
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 TCF/LEF:  MCF-7 cells were plated at a density of 2x105 cells/60mm dish and 
were allowed to incubate for 6 hours to adhere.  The cells were to be transfected with 
the TCF/LEF construct 24 hours before harvesting so we had to treat cells with SP 
accordingly.  That meant that 48 hours before we transfected the cells we treated the 72 
hour time point with SP.  All cells were placed in fresh 10% medium after transfection.  
The cells were washed in ice cold PBS and harvested in the lysis buffer provided in the 
kit.  We followed the protocol in the kit exactly.   
P50 and P65 s-nitrosylation 
 We plated MCF-7 cells at a density of 1.2x106 cells/60mm dish and allowed them 
to incubate overnight to adhere.  The cells were then transfected with both p65 and p50 
plasmids according to the Lipofectamine/Plus protocol from Invitrogen.  Following 
transfection the cells were treated with the dose of SP and for the duration indicated.  S-
nitrosylated p65 and p50 was determined by the Biotin Switch Method described in 
detail in Chapter 1.  Once the s-nitrosylated proteins were isolated, SDS-Page 
electrophoresis was used to separate the proteins and western blotting was used to 
determine protein levels. 
IκBα nitration 
 We plated cells at a density of 1.2x106 cells/60mm dish and were allowed to 
incubate overnight to adhere.  Cells were transfected with a Myc tagged IκBα plasmid 
according to the Lipofectamine/Plus protocol from Invitrogen.  Once cells had been 
treated with the dose of SP and for the duration indicated they were washed three times 
in ice cold 1X PBS and lysed in buffer containing 50mM Tris pH 7.4, 150mM NaCl, 1% 
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NP40, and a 1X concentration of phosphatase and protease inhibitors.  Samples were 
centrifuged for 20min at 13,200 at 4˚C and the supernatant was transferred to a clean 
1.5ml eppendorf tube.  Myc-IκBα was then immunopurified with anti c-Myc overnight at 
4˚C.  The beads were washed twice in ice cold lysis buffer and once in ice cold 1X PBS.  
All of the PBS was removed and the beads were boiled in 35µl of laemmli sample 
buffer.  The sample was then resolved on a 10% SDS-Page gel and after transfer the 
resulting membrane was probed for anti-nitrotyrosine.      
Growing cells as Spheroids 
 5ml of 1% agarose in RPMI without FBS or Pen/Strep was used to coat the 
bottom of 100mm petri dishes and placed in the incubator to solidify.  During that time 
the cells were trypsinized and counted.  MCF-7 cells were plated at a density of 1.5x105 
cells/ml of medium on top of the agarose layer (10ml/dish).  The dishes were placed on 
a rocker in the incubator and allowed to grow for three days before they were used in 
experiments.  To harvest the spheroids the medium containing the floating spheroids 
was removed from the dish and centrifuged at 1,000 RPM for 5min.  The supernatant 
was removed from the top of the cell pellet and then the cells were resuspended in 5ml 
of ice-cold PBS to wash.  The wash step was repeated twice.  After removing all of the 
PBS from the wash steps, the cells were lysed in laemmli sample buffer, sonicated and 
then boiled for 5min.      
Western Blot Analysis 
Protein was extracted from flash frozen tumors using a pestle and mortar in 20 
ml/g tumor RIPA lysis buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% 
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sodium deoxycholate, 0.1% SDS, 5 mM EDTA) and processed under reducing 
conditions. Alternatively tissue culture cells were harvested in 1X Laemmli sample 
buffer.  Proteins were resolved by SDS-polyacrylamide gel electrophoresis and 
transferred to nitro-cellulose membranes. Membranes were incubated with the primary 
antibody of interest overnight at 4°C. Blots were developed using IR 700 or IR 800 
conjugated secondary antibodies (Rockland Immunochemicals, Gilbertsville, PA) diluted 
1:10,000 and imaged/analyzed using the Odyssey Licor system. 
Cell Survival Assay (WST and Clonogenic Assay 
 WST-1:  Cells were washed, trypsinized and counted.  This assay is performed in 
a 96 well plate and samples are plated in triplicate.  1x103 cells/well in 200µl of medium 
were plated and allowed to incubate overnight to adhere.  When we were ready to 
determine cell viability 4µl of WST-1 reagent was added to the well and allowed to 
incubate for 3 hours before.  The formazan that is formed by metabolically active cells is 
then quantified by spectrophotometer at 420-480nm.  For our experiments involving SP 
treated cells, if the treatment was for longer than 24 hours, new SP was put on the cells 
every day until the end of the treatment period. 
 Clonogenic Assay:  cells were trypsinized and plated in 10cm dishes.  200 cells 
were plated in the control dishes while 500 cells were plated in the treatment groups.  
Dishes were treated with varying concentrations of SP 16 hours after plating.  When the 
colony size reached 50 cells, cells were fixed in -20˚C methanol, stained with 0.5% 
crystal violet and counted. 
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 Ex-vivo Clonogenic Assay:  Tumors were harvested and minced into small 
pieces with a scalpel in medium without serum.  The pieces were washed twice in 
medium and then the pieces were agitated in medium containing 0.08% collagenase 
and 0.5% Trypsin for 40min at 37˚C.  DNase to 0.06% was added to the medium and 
the cells were strained through a .70µM cell strainer.  The resulting single cell 
suspension was counted, excluding RBC’s, and plated at several concentrations.  The 
plating efficiency of this type of experiment is very poor so we plate many more cells 
than we would for the tissue culture assay.  We plated 2k, 5k, 10k, and 20k cells per 
100mm dish.  The dishes were fixed and stained as above when colonies reached 
approximately 50 cells. 
Nuclear Preps 
 The cells were plated in 100mm dishes and treated accordingly.  When they 
were ready to be harvested they were washed twice with ice cold PBS.  Cells were then 
scraped into 1ml PBS and transferred to a microcentrifuge tube and centrifuged for 
5min at 2500 RPM at 4◦C.  The cell pellet was resuspended in 1ml of PBS and 
centrifuged for 5min at 2500 RPM.  The supernatant was completely removed after this 
rinse.  3x pellet volume of ice cold solution I (10mM Tris-HCl pH7.5, 25mM KCl, 2mM 
Mg Acetate, 1mM DTT, protease inhibitors), about 150µl, was added to the pellet to 
resuspend.  The slurry was then centrifuged for 3min at 3500 RPM and the resulting 
supernatant was discarded.  Again we added 3x volume of solution I to resuspend the 
pellet and then incubated the tube on ice for 10min.   The cells were then homogenized 
ten times with a 27G1/2 needle.  The homogenate was then centrifuged 5min at 3500 
RPM with the resulting pellet containing the nuclei.  The cell pellet was resuspended in 
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150µl of Solution II (10mM Tris-HCl pH 7.5, 400mM KCl, 2mM Mg Acetate, 20% 
Glycerol, 1mM DTT, protease inhibitors) and incubated on ice for 10min after which it 
was centrifuged for 5min at 12000 RPM.  The supernatant is the nuclear extract.  
Aliquot and store at -80◦C.  
EMSA 
We purchased the EMSA buffer kit and the IRDye 700 labeled oligos from Li-Cor 
and followed the general protocol.   A 5% TBE native acrylamide gel in 0.5X TBE was 
pre-run for 30min at 70V (while the binding reactions are being prepared).  20µl 
reactions were set up in the following order:  H2O, 2µl 10X binding buffer, 2µl of 25mM 
DTT/2.5% Tween 20, 1µl of 1µg/µl Poly (dIdC), 1µl of 1% NP-40, 1µl of 100mM MgCl2, 
1µl of IRDye oligo, and 5µg of nuclear extract.  The tubes were mixed and incubated in 
the dark at room temperature for 20min.  2µl of 10X orange loading dye was added to 
each reaction tube and samples were loaded on to the gel and separated at 70V.  The 
gel box was covered to keep it in the dark and the gel was visualized using the Li-Cor 
Inrared imager after 1hr. 
Flow Cytometry 
 Cells were plated at a density of 2.5x105 cells/100mm dish and allowed to adhere 
overnight.  We wanted to plate at a density where the cells would be 50-60% confluent 
on the day we harvested.  Cells were treated accordingly with SP on the days leading 
up to harvest.  When we were ready to harvest cells we washed the dishes with PBS, 
trypsinized and counted the cells.  The cells were centrifuged and then resuspended in 
PBS at 106/ml.  1ml of cells was centrifuged and the supernatant was removed.  The 
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pellet was resuspended in 0.5ml of PBS and vortexed at high speed in order to achieve 
a single cell suspension.  While vortexing 4.5ml of -20°C 70% ethanol was added 
dropwise into the cell suspension.  The cell suspension was vortexed for an additional 
minute after the addition of all of the ethanol.  The cells could be stored overnight at 4°C 
or stained.  To stain the cells they were first centrifuged and then resuspended in PBS.  
This process was repeated twice.  The cell pellet was then resuspended in 1ml of 
propidium iodide/RNase staining solution (To 10ml of 0.1% Triton-X/PBS add 2mg of 
DNase-free RNase A and 0.2ml of propidium iodide stock (1mg/ml).  Cells were stained 
for a minimum of 1 hour and then analyzed for cell cycle by the Massey Cancer Center 
Flow Cytometry Shared Resource Core. 
Flank Tumor Xenografts 
 See Chapter 2.  For tumor volume measurements N= number of animals, n= 
number of tumors. 
Biotin Switch 
 See Chapter 2   
RESULTS 
MCF-7 and MDA231 contain PKG that is activated by treatment with SP 
 The main signaling pathway activated as a result of NO production is binding to 
sGC and subsequent activation of PKG.  First we determined whether or not our cells 
expressed PKG and secondly determined if the activity changed in the presence of SP.  
Western blot analysis of PKGI in MCF-7 and MDA231 cells confirmed the expression of 
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PKGIβ (Figure 3.3A).  The phosphorylation of VASP has been identified as a useful 
marker for cGMP induced cell death due to increased PKG activity and so we measured 
pVASP as a marker for activity in our cells after treatment with SP [113].   We had 
difficulty detecting endogenous pVASP so we transfected VASP into MCF-7 cells and 
treated them 24 hours after transfection with SP.  Western blot analysis of the cell lysate 
showed a 10-fold increase in pVASP 6 hours after treatment with 50µM SP (Figure 
3.3B).   Having determined PKG activity is increased in our cell lines as a result of 
recoupling NOS we wanted to examine some of the downstream targets. 
Activation of PKG results in decreased β-catenin signaling 
 We described in the introduction how a reduction in Cyclin D1, β-catenin 
signaling and an increase in p21/waf1 has been observed in colon cancer cells upon 
induction of PKG activity and are responsible for the cytotoxic effects seen in colon 
cancer cells.  Since we determined that we were getting PKG activity in our cells after 
SP treatment we looked for changes in the levels of these proteins.  Western blot 
analysis of β-catenin confirms that protein levels decline over time when cells are 
treated with SP both in MCF-7 and MDA231 cells, and that this effect is reversed when 
we treat cells with KT5823 in conjunction with SP (Figure 3.4A).  KT5823 is a potent, 
selective, cell permeable inhibitor of PKG (IC50 20nM in vitro) and should therefore block 
the effects of SP if the actions are through PKG.  Western blot analysis of tumor cell 
homogenates also confirmed that we lose β-catenin protein in flank tumor xenografts of 
MCF-7 cells (Figure 3.4B).  To confirm that we were getting decreased β-catenin 
signaling at the level of transcription we used a Luc TCF/LEF reporter construct.  When 
we transfected the luciferase reporter construct into MCF7 cells we were able to see  
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decreased β-catenin signaling in SP treated cells that was also reversed by KT5823 
(Figure 3.5).  We used 100µM 8-Br-cGMP, a cGMP analogue that is resistant to PDE’s, 
as a positive control.  We were unable to conduct this experiment in MDA231 cells as 
the transfection efficiency was too poor. 
When we examined signaling downstream of β-catenin we saw increased p21 
protein levels in MCF-7 cells, abolished by KT5823, but did not see any changes in 
cyclinD1 protein levels (Figure 3.6).  In our analysis of MDA231 cells we saw that there 
were no changes in p21 but we did detect increased p27 protein levels at 24, 48 and 72 
hours post SP treatment.   Several other groups had analyzed cell cycle distribution in 
cells after PKG activation and shown G1 arrest, which was mainly though loss of cyclin 
D1 protein.  We did not see loss of cyclin D1 but we did see changes in p21 and p27 
and as both play a role in cell cycle progression we examined our cells by flow 
cytometry to determine if cells were arresting at some point in the cell cycle which could 
help explain the cytotoxic effects.  We found that neither MCF-7 nor MDA231 cells 
showed any significant changes in cell cycle distribution when treated with SP (Figure 
3.7).  
Sepiapterin reduces NF-κB activity 
Previous studies have demonstrated that when the p50 or p65 subunit of NF-κB 
is S-nitrosylated there is decreased binding of the complex to DNA.  Our initial 
experiments tested whether SP had an effect on the level of S-nitrosylated p50 and/or 
p65 in our cells.  MCF-7 cells were co-transfected with WT p65 and p50 and on the 
following day treated with varying concentrations of SP for 6h. The cells were harvested  
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in RIPA buffer and analyzed for S-nitrosylated p65 and p50 by the biotin switch method 
described in methods.  The results showed a dose dependent increase in S-nitrosylated 
p65, but we were unable to detect any S-nitrosylated p50 (Figure 3.8A).  To determine if 
the increased p65 S-nitrosylation had any effect on NFκB activity we transfected a 
luciferase based NFκB reporter construct into MCF-7 cells and treated them with a 
range of SP concentrations.  Treating cells with SP resulted in a dose dependent 
decrease in NF- B luciferase activity with a maximal inhibition of 40% at 50 M (Figure 
3.8B). 
To verify that the S-nitrosylation of p65 was responsible for the decreased NFκB 
activity measured by luciferase assay we constructed a p65 plasmid with a C38S 
mutation.  This Cysteine was demonstrated to be S-nitrosylated in previous studies and 
p65 C38S has been shown to bind to DNA and activate transcription [114].  We co-
transfected MCF-7 cells with the luciferase based NF B reporter construct and the 
mutant p65 and 24 hours later we treated the cells with SP.  We determined by 
measuring the NF B luciferase activity that the p65 C38S mutant treated with SP 
behaved like untreated cells (Figure 3.9).  These data indicated that the S-nitrosylation 
of p65 due to recoupling of NOS decreased NFκB activity.  One mechanism by which 
NFκB exhibits its anti-apoptotic activities is through upregulation of Bcl-2.  Now that we 
had demonstrated decreased NFκB activity in tumor cells after treatment of SP we 
wanted to assess the effects on some of the downstream targets.  We homogenized 
several tumors and by western blot determined that Bcl-2 was expressed in 
substantially lower amounts in tumors treated with SP than in untreated tumors (Figure 
3.10).     
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Sepiapterin reduces STAT3 nuclear translocation in MCF-7 cells 
 STAT3 is another transcription factor known to be constitutively activated in 
breast tumor cells and has been shown to be manipulated by ROS so we treated MCF-
7 cells with 20µM SP for 24, 48 and 72 hours and assessed the level of STAT activation 
in two ways:  phosphorylation of Tyr705 and nuclear translocation.  Western blot 
analysis of pSTAT3 showed a decrease in phosphorylation at all time points examined 
post treatment (Figure 3.11A).  As the result was only marginal we then decided to 
prepare nuclear extracts to examine the level of STAT3 in the nucleus.  The gel shift 
clearly indicates that DNA binding of STAT3 is reduced in cells that had been treated 
with SP (Figure 3.11B).  Putting this in the context of the rest of our data shows that 
recoupling of NOS leads to downregulation of STAT3 signaling.     
SP inhibits cell growth both in vitro and in mouse tumor xenografts 
Discussed in detail previously, PC3 cells react in a pro-proliferative manner when 
given BH4 and NO donors can have a pro or anti-apoptotic effect depending on a 
number of factors. The above studies show that we are able to manipulate the activity of 
several important pro-survival transcription factors and now we wanted to determine the 
effects of SP on cell proliferation.  We first performed a WST assay to determine the 
effects of SP on metabolically active cells.  In cells receiving a 50µM does of SP we saw 
a growth inhibitory effect in MDA-231 cells and a cell death effect in MCF-7 cells (Figure 
3.12). 
Carrying our tissue culture studies a step further we used a clonogenic assay to 
determine actual cell death.  Figure 3.13A shows that in single cells plated and treated  
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with SP we saw a concentration dependent decrease in MCF7 and MDA231 tumor cell 
survival.  Several key controls were included in these experiments, LNNA, NPH4, N-
Acetylserotonin (NAS) and KT5823.  Treating cells with 200nM LNNA to block NOS 
activity in these cells completely eliminated the toxicity of SP which confirms that SP is 
working through NOS.  NPH4 has the same ability as BH4 to be reduced but will not 
bind to NOS, and in our experiments controls for anti-inflammatory effects.  If BH4 were 
just having an anti-inflammatory effect then we should see the same results in the 
clonogenic assay in cells treated with NPH4.  The results obtained determined that the 
effect of BH4 is through NOS and not due to BH4 as an anti-inflammatory as NPH4 had 
no effects on cell viability.  These data also showed that KT5823 significantly restored 
cell viability (Figure 3.13B).   
 Both MDA231 and MCF7 cells can be grown as xenografts in nu/nu mice (called 
nude mice due to their lack of hair).  Nude mice have a genetic mutation that causes 
deteriorated or absent thymus resulting in an inhibited immune system, and have no 
rejection response to tissue xenografts.  We injected cells into the flanks of the mice 
and waited for the tumor to reach a palpable volume.  We treated some of the animals 
for 48 hours with 1mg/kg/ml of SP in their drinking water and then harvested the tumors 
and plated them for an ex-vivo clonogenic assay.  To be certain that SP was not having 
off target effects we gave the animals NAS in conjunction with SP.  NAS is a sepiapterin 
reductase inhibitor which blocks SPs conversion to BH4.  Figure 3.14 shows that when 
animals bearing MDA231 flank xenografts are treated with 1mg/kg/ml of SP for 48 hours 
that there was a significant decrease in clonogenicity which was blocked by a 10mg/kg 
i.p. injection of NAS.  From both our tissue culture and ex-vivo clonogenic data we  
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concluded that the cytotoxic effects of SP are mediated through recoupling of NOS and 
at least partially through PKG. 
Having determined that SP exerted a cytotoxic effect on tumor cells grown as 
flank xenografts, we then wanted to assess the effects of SP on tumor growth over an 
extended period of time so we generated MDA231 flank xenografts and allowed them to 
grow unhindered until they reached approximately 150mm3 in volume.  The animals 
were then divided into two groups:  control and SP treated.  We measured the tumor 
volumes of the animal every 2 days until we had to sacrifice the animals as a result of 
the tumors getting too large.   We saw that there was a significant delay in tumor growth 
in animals with SP in their drinking water versus control animals (Figure 3.15).   
Signaling in MCF-7 cells 
 We had variable results when we used cell monolayers in assessing β-catenin 
protein levels and therefore we decided to grow our MCF-7 cells as spheroids.  Growing 
cells as spheroids has the advantage of the cell growing in three dimensions instead of 
two, potentially changing how it interacts with neighboring cells.  MCF-7 cells are 
amenable to growing as spheroids and the process is described in the methods section. 
Discussion 
 SP, through recoupling of NOS, stimulates the catalytic activity of NOS as an NO 
synthase and reestablishes sGC signaling while at the same time moving the cellular 
environment away from pro-proliferative and inflammatory to anti-inflammatory and pro-
death.  Here we showed that treatment of MCF-7 and MDA231 cells with SP, whether in 
tissue culture or in mice, resulted in decreased clonogenicity.  This effect is mediated at  
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least in part by PKG signaling through β-catenin and also through redox manipulation of 
two very important transcription factors in breast cancer, STAT3 and NFκB. 
Studies have shown that MDA231 cells express all three NOS isoforms, but there 
are conflicting reports on MCF-7 cells.  Some reports have shown all three, some NOSI 
and NOSIII, and others just NOSIII (Mathews, NE 2001 Nakatani  K 2004 Fiszman G I 
2007).  We did not evaluate NOS expression in our cell lines but the literature has 
shown that BH4 has equal affinity for the three isofroms.  Studies of the binding site 
interactions of BH4 and NOS in crystallized structures showed similar interactions 
between all three isoforms and they suggest that any difference in affinities of BH4 for 
NOS would be minimal and be as a result of changes in the hydrophobic interactions at 
the binding site (Kotsonis P 2001).  This data suggest that as long as cells express 
NOS, regardless of the isoform, that SP should effectively alleviate uncoupling.    
The experiments with NPH4 (Figure 3.13) are important to our findings.  SP is 
not acting like just another anti-inflammatory.  NPH4 and NAS clearly show that the 
effects of SP are as a direct result of modulation of BH4 levels which has an impact on 
the product of NOS catalytic activity.  What we have shown through treatment of cells 
with SP is that we have a direct impact on the NOS catalytic cycle and cellular 
metabolism. 
β-catenin downregulation 
We examined several possible mechanisms for the downregulation of β-catenin 
signaling.  GSK3β resides in complex with β-catenin and when GSK3β is 
dephosporylated on Ser9, an inhibitory phosphorylation, it is then able to phosphorylate 
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β-catenin on Ser33, Ser34, and Thr43 targeting it for ubiquitination and proteosomal 
degradation.  The inhibitory GSK3β ser9 phosphorylation is due to pAKT signaling as 
seen in figure 3.2 and western blot analysis of pAKT and pβGSK3 in the breast tumor 
cell lines we studied demonstrated there is no change in phosphorylation or protein 
level in either protein after treatment with SP, indicating a different mechanism (data not 
shown). 
Several other potential mechanism of β-catenin downregulation remained 
unexplored in our cell lines.  There has been some evidence that PKG can directly 
phosphorylate β-catenin leading to its degradation [115].  The PKG inhibitor KT5823 
blocks the downregulation of β-catenin and future studies could elucidate the role of 
PKG on phosphorylation of β-catenin through western blot of phosphorylation sites 
combined with mutation analysis.  A mechanism that may be involved, as we do not see 
complete restoration of β-catenin signaling in the presence of KT5823, is the s-
nitrosylation of β-catenin.   Previous studies have demonstrated that β-catenin can be s-
nitrosylated resulting in loss of function [116].  It is also possible that loss of β-catenin is 
occurring in response to STAT3 downregulation.  Analysis of the gene promoter of β-
catenin shows multiple STAT3 binding sites and it has been shown that loss of pSTAT3 
results in loss of β-catenin [117].     
p21 and p27 upregulation 
 The role that p21/waf1 plays in the cytotoxic effects of SP needs to be examined 
further.   p21 prevents cancer cell growth due to its ability to transiently or permanently 
stop proliferation.  p21 accumulation contributes to maintenance of the arrest at G1-S 
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and G2-M through inhibition of cyclin dependent kinases that regulate these cell cycle 
transitions.  It was initially identified to be transcriptionally upregulated by p53 in 
response to DNA damage and is an integral part of the p53-mediated growth-arrest 
pathway [118].  More recent studies have shown that p21 can also be induced by 
various transcription factors and subsequently mediate growth arrest, senescence and 
apoptosis in a p53 independent manner [119, 120].  p21 and p27 have similar functions 
but their mechanisms of induction and regulation are distinct.  While studies have 
shown both G1 and G2 to be regulated by p21, p27 has only been demonstrated to be 
involved in the G1/S phase transition [121].   
As discussed, p21 can exert its inhibitory effects throughout the cell cycle as well 
as being involved in other modes of cell signaling (Figure 3.16).    A large proportion of 
the data on p21 shows that it inhibits the cell cycle during the G1 phase, that it has other 
actions may eplain our FACS analysis.  These data showed that we were not enhancing 
the G1 population, at least in the timeframe we were looking at, 0-72 hours.   We only 
examined the cell cycle out to 72 hours but recently we have discovered that some 
researchers are seeing G1 arrest after 5 days even though p21 has been upregulated 3 
days prior [122].  Our future studies will examine carry treatment of SP out further to 
determine if we see G1 arrest at later time points. 
 Our future studies will examine the mode of cell death.  The cells were not 
undergoing apoptosis, at least out to 72 hours, as the sub G1 population remained the 
same.  To further rule out apoptosis in these cells we looked at PARP and Caspase 3 
cleavage at up to 72 hours.  We saw no changes in cleavage of either protein after 
treatment with SP (data not shown).  Experiments now focus on determining if our cells  
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are undergoing senescence.  p21/waf1 not only regulates cell cycle progression but is 
also involved in regulating cellular senescence and may be a possible explanation for 
the effects seen in our cells after treatment with SP [123].     
Inhibition of NFκB promoter binding 
NFκB constitutive activation is a hallmark of various types of tumors and 
inhibition of its activity remains a hot topic.  The activation of NFκB is inherently 
complex, given the multitude of signaling pathways and crosstalk.  Although we have 
shown that NFκB activity is reduced in MCF-7 cells after treatment with SP the 
transcriptional outcome is still not understood.  We were able to show that Bcl-2 is 
downregulated in MCF-7 xenografts but we are not sure of the mechanism.    
We showed that we could manipulate p65 and therefore could reduce NFκB DNA 
binding but we had also hoped to show that NOS uncoupling resulted in NFκB activity 
being regulated by nitration as well.   As described previously, our laboratory had 
demonstrated a mechanism by which NFκB became transcriptionally active following 
nitration of IκBα.  The hypothesis was that by changing the redox environment of the 
cell we could switch from one activating post-translational modification to an inactivating 
post-translational modification, but attempts to manipulate the nitration of IκBα with SP 
have been unsuccessful so far.  
Inhibition of STAT3 translocation to the nucleus  
We show that SP decreased pSTAT3 and reduced the amount of STAT3 in the 
nucleus.  Future studies will determine the role of changing the redox state of the cell on 
STAT3 activity.  Changing the redox state of the cell potentially alters the activity of 
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RTK’s through changes in PTP’s activity.  It has been demonstrated that PKG can 
activate SHP2 and this is a mechanism that could be potentially involved in the down 
regulation of STAT3 in our cells.  JAKs, which are responsible for STAT3 activation, are 
highly redox sensitive and have been shown to be NO sensitive and to be activated to 
various degrees based on the level of oxidants in the cell [124].  There are four 
cysteines in the catalytic domain of JAK2 that have shown the potential to regulate 
activity [125].    
Other considerations 
Our studies have focused on manipulating the BH4 levels to restore the sanctity 
of NOS.  As we discussed in the introduction NO signaling is ubiquitous and is 
concentration and context dependent.  There have been other groups who examine NO 
signaling from an inhibitory side.  Pickert et al. examined the effects that inhibition of 
GTP-CH had on angiogenesis and tumor growth.  They demonstrated that shRNA 
mediated knockdown and pharmacological inhibition of GTP-CH resulted in decreased 
angiogenesis and tumor cell death [126].  Several concerns arise when reviewing the 
data.  The first is that the concentration of the SR inhibitor used is 1mM all the way up to 
50mM which is extremely high and would tend to suggest having several off target 
effects.  There is an important point that we believe is missed and that our results help 
to shed some light on.  That NOS is uncoupled in these cells and that by inhibiting GTP-
CH we don’t know what is happening to the BH4:BH2 ratio.  They never look at the 
ratio.  Taking another look at the data, the shGCH1 was only mildly effective in knocking 
down protein levels of GTP-CH. Lastly, the colony forming assay showing that shGCH1 
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inhibits colony formation is insignificant and we would suggest that the effects seen in 
the animals are through an undetermined mechanism. 
The results seen in the two different cell lines were extremely similar except for 
the WST assay.  There are several differences between MCF-7 and MDA231 cells.  
MDA231 cells are ER-negative and highly invasive while MCF-7 cells are ER-positive 
and weakly invasive.  MDA231 are p53 mutant at 280K while MCF-7 cells are p53 WT, 
suggesting a potentially p53 independent mechanism of action.  The WST-1 alludes to 
different mechanisms of action of SP on cell metabolism between the two cell lines.  
After 3 days of SP treatment the MCF-7 cells had all been arrested or killed off and this 
was a much greater effect than what we saw in the clonogenic assay.  The only 
difference in the way we treated the cells was that in the clonogenic assay the cells only 
receive one dose of SP whereas in the WST assay the cells received fresh SP every 
day.  Future studies should consider taking a look at concentration of NO generated in 
the cell, different dosing regimens and the role of p53 plays in the cytotoxic effects 
observed.     
We used the clonogenic assay as the ultimate determinant of cell fate as studies 
measuring the tumor volume are difficult to assess.  Cells may be dying but the tumor 
may swell due to poor lymphatics resulting in fluid accumulation.  When we consider the 
tumor volume measurements, some of the animals developed tumors faster than others 
and this led to differences in the tumor size at the beginning of treatment.  Closer 
examination of the data suggest that we may have seen an enhanced effect on tumor 
cell proliferation had we started some of the animals on SP when the tumors were 
smaller.  The animals whose tumors were smaller seemed to have a greater response 
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in terms of reduction in tumor growth with SP.  Studies in the next section and future 
studies will focus on issues like this and some of the other potential therapeutic uses of 
SP.   
A big piece to the puzzle that was never determined was whether the effect of SP 
was due to actions on the stromal cells, the tumor cells, or both.  Studies have shown 
that BH4 promotes tumor angiogenesis, however these studies were conducted on the 
stromal cells and not on the immortalized tumor cells [127].  Further studies are needed 
to determine the full effects of BH4 supplementation on cancer cells in the context of a 
“normal” tumor environment: immune cells, vascular cells and tumor cells all interacting. 
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Chapter 4: 
The Therapeutic Potential of Tetrahydrobiopterin 
 
  
Introduction 
 The focus of this chapter is on potential uses of BH4/SP as a therapeutic agent in 
the treatment of colitis induced colorectal cancer.  Previous chapters have 
demonstrated how NOS is uncoupled in tumor cells and that exogenous SP helps to 
eliminate the encouragement to proliferate by the tumor microenvironment.   The theme 
has been the same from the beginning:  Tumor cells are supported by their pro-
inflammatory, pro-proliferative environment which not only contributes to NOS 
uncoupling but creates a cycle by which NOS then exacerbates it.  This chapter will 
detail the effects of SP in animal work we performed with DSS induced colitis and AOM 
generated colon tumorigenesis. 
Role of tetrahydrobiopterin in NOS recoupling and inflammatory disease  
Superoxide generation by eNOS has been demonstrated in several inflammatory 
disease states, including atherosclerosis, hypertension and diabetes [128-130].  Several 
mechanisms are employed to enhance BH4:BH2 ratios in cells to alleviate this.  BH4 
supplementation has been shown to be effective in reducing NOS uncoupling and 
improving endothelial dysfunction in hypercholesterolemia, diabetes, hypertension, 
coronary artery disease and heart failure [131-133].  BH4 has also been shown to 
reverse endothelial dysfunction in post-ischemic tissues.   
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The development of the hph-1 mouse deficient in GTP-CH has been used to 
study the human condition known as DOPA responsive dystonia which is characterized 
by low levels of BH4, catecholamines, and serotonin with low levels of tyrosine 
hydroxylase protein ([134].  These animals also exhibit hyperphenylaninemia. 
 The hph-1 mouse has been a useful tool for studying BH4 deficiency in 
cardiovascular disease and pulmonary hypertension.  Pulmonary hypertension is 
characterized by vascular remodeling and vasoconstriction and loss of NO 
bioavailability has been demonstrated.  The hph-1 mouse was used as a model of 
pulmonary hypertension as it had normal eNOS levels but reduced NO and the BH4 
deficiency caused pulmonary hypertension.  What Khoo et al. showed was that in hph-1 
mice augmented by overexpression of GTPCH, BH4 deficiency was reduced and 
pulmonary hypertension prevented [135].  The hph-1 mouse could prove a useful tool in 
study NOS dysregulation in our lab. 
DSS induced colitis and AOM induced colon cancer 
As discussed, inflammation provides initiating and promoting stimuli and 
mediators, generating a tumor-prone environment.  In this animal model, DSS provides 
the inflammatory environment while a single exposure to AOM provides the initiating 
event. In combination the latency period for tumor development is dramatically reduced 
In colon tumorigenesis inflammatory bowel disease (IBD) is one of three high risk 
conditions for the development of colorectal cancer (CRC), the others being familial 
adenomatous polyposis coli (APC) and hereditary non-polyposis CRC.  A hallmark of 
inflammation and oxidative stress is increased nitration of proteins, and enhancement in 
the expression of iNOS in epithelial and invading inflammatory cells results is likely the 
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cause  [136, 137].  It has been demonstrated in colitis that motility is affected by 
nitration and inhibition of the Cav1.2 calcium channel of colonic smooth muscle cells 
[138]. ROS/RNS scavengers and inhibitors of NOS have been shown to attenuate 
chemically induced IBD.  Another study demonstrated that dietary supplementation with 
nitrite ameliorated DSS-induced colitis ([139].   
We have demonstrated the role of NOS uncoupling in inflammation and the 
effects it has on the tumor environment.  NFκB is intertwined in the inflammatory 
response and β-catenin is associated with colon cell proliferation as described earlier so 
we decided to determine the effects on DSS induced colitis and AOM induced 
tumorigenesis in the presence of SP.   
Rob Cardnell, PhD and Ross Mikkelsen, PhD contributed to the following  
METHODS 
Mouse model of colitis: 
 Short-term colitis was induced by the addition of 2.5% dextran sodium sulfate 
(DSS; USB Corporation, Cleveland OH) to the drinking water of 5-6-week-old C57 BL/6 
male mice for a period of 7 days.  Mice designated for SP (Schircks Laboratories, 
Switzerland) treatment received 4mg/100ml SP in their drinking water continually 
starting 3 days before DSS treatment.  All animals were monitored daily for weight, stool 
consistency and the presence of blood in the excreta.  Disease activity index (DAI) was 
determined by combining scores for weight loss, stool consistency and bloody excreta 
as follows:  Weight loss (0: <1%, 1: 1-5%, 2: 5-10%, 3:10-15%, 4: >15%); Stool 
consistency (0: normal, 2: loose, 4: diarrhea); Blood in excreta (0: normal; 2: reddish, 4: 
bloody).  Long-term colitis/carcinogenesis was induced by the I.P. injection of AOM 
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(10mg/kg) seven days prior to the onset of DSS treatment; three week long courses of 
DSS were given as above separated by 2 weeks of DSS-free water.  Animals were 
sacrificed 3 weeks after the final DSS treatment, 77 days after AOM treatment.  Mice 
designated for SP treatment received 4mg/100ml SP in their drinking water continually 
starting 3 days before DSS treatment.  All animals were monitored daily for weight, stool 
consistency and the presence of blood in the excreta.  All procedures were approved by 
the Institutional Animal Care and Use Committee of Virginia Commonwealth University 
and conformed to the guidelines established by the National Institutes of Health, 
protocol numbers AM10080 and AM10185. 
BH4/BH2 analysis:  
 See Chapter 2 
cGMP ELISA:  
 See Chapter 2 
Isometric Tension Recording: 
Approximately 1.5-cm strips of distal colon were suspended in the longitudinal 
direction in an organ bath containing 15 ml of Krebs solution (118 mM NaCl, 4.6 mM 
KCl, 1.3 mM NaH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11 mM glucose, and 2.5 mM 
CaCl2), bubbled continuously with carbogen (95% O2 and 5% CO2) at 37°C under a 
resting tension of 1 g and equilibrated for a period of 1 h. Isometric contractions were 
recorded by a force transducer (model GR-FT03;Radnoti, Monrovia, CA) connected to a 
personal computer using Acknowledge 382 software program (BIOPAC Systems, Santa 
Barbara, CA). After equilibration in Krebs solution, tissues were incubated for 30 min in 
Ca2+-free high-potassium solution (80 mM) in which equimolar NaCl was replaced by 
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KCl containing 0.1 mM EGTA and changed every 15 min. Cumulative dose-dependent 
contraction responses to CaCl2 (10 μM to 10 mM) were performed in distal colon strips 
depolarized by Calcium-free high-K+ (80 mM)-physiological saline solution (without 
EGTA). The cumulative concentration–dependent increases in tissue tension by CaCl2 
was analyzed among tissue strips isolated from control, DSS, DSS with SP and SP 
alone treated groups of mice.  Experiments performed by Gracious Ross, PhD. 
Histopathology 
Colons were excised from animals, flushed with PBS, cut longitudinally, rolled 
into “swiss rolls” and immediately flash frozen in liquid N2.  Frozen swiss rolls were 
embedded in OCT and cryosections prepared.    
For macrophage detection, frozen sections were fixed in ice-cold acetone for 10 
min.  After serum blocking for 60 min, the sections were stained with primary mAb for 
F4/80 (5 mg/mL, AbD Serotec) overnight at 4oC, followed by incubation with Alexa594-
labeled donkey anti-rat secondary IgG (Invitrogen) at RT for 1 hour. A negative staining 
control was performed by incubation with isotype control Abs. 
 For Hematoxylin and Eosin (H&E) staining, cryosections (20 m) were fixed in 
4% paraformaldehyde, submerged in Modified Mayer’s Hematoxylin (Richard Allan 
Scientific), destained in acid ethanol, stained with eosin, dehydrated and mounted with 
permount.  Images were captured using the Ariol Digital Pathology Platform.  
Gene expression analysis 
 Colons were excised, flushed with PBS and flash frozen using liquid N2.  mRNA 
was extracted using the Qiagen RNase Mini Kit per the manufacturer’s instructions.  
cDNAs were generated using the Invitrogen SuperScript III First-Strand Synthesis 
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System for RT-PCR per the manufacturer’s instructions using 1ug total RNA per 
reaction and Oligo(dT)20 primers.  For quantitative PCR analysis, transcription profiles of 
IL-17α, IL-1β, and IL-6 were assessed on an ABI prism 7900HT Sequence Detection 
System using TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, 
CA). Primers and FAM-labeled probe sets were obtained as pre-developed assay 
reagents from Applied Biosystems: IL-17α, Mm00439618_m1, IL-1β, Mm01336189_m1, 
IL-6, Mm99999064_m1. The PCR was started with 2 min at 50 °C and an initial 10 min 
denaturation at 94 °C, followed by a total of 40 cycles of 15 sec denaturation at 94 °C, 
and 1 min of annealing and elongation at 60 °C. All measurements were performed in 
triplicate wells and repeated three times. Gene expression was quantified relative to the 
expression of the housekeeping gene β-actin, and normalized to that measured in 
control cells by standard 2(-ΔΔCT) calculation. 
Statistics 
For contraction measurements, data from different groups were analyzed by two way-
ANOVA followed by Bonferroni's post-test. P ≤ 0.05 was considered significant.  For all 
other experiments, data are shown as mean +/-SEM with P values calculated by 
student’s t-test. 
RESULTS 
SP treatment ameliorates DSS-induced colitis 
To determine the effect of SP upon experimental colitis animals were placed in 
four groups drinking water containing DSS, SP, DSS and SP or untreated water and 
were monitored for the development of colitis. Colitis was measured by daily recordings  
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of weight, stool consistency, and the presence of blood in the excreta. As shown in 
Figure 4.1A, by day 7 animals receiving DSS have lost 14% of their starting body 
weight. The weight loss in DSS treated animals was prevented by the addition of SP to 
the drinking water. Similarly, the disease activity index (Figure 4.1B) was significantly 
increased in only the DSS treated animals at day 7. The development of DSS-induced 
colitis and its partial mitigation by co-treatment with SP was also monitored by H&E 
staining of frozen sections of colons from treated animals. As shown in Figure 4.2, a 
loss of villi and crypts is observed in the DSS alone treated colon and co-treatment with 
SP mostly mitigates this change in colonic morphology. Separation of the muscle and 
muscularis mucosae is predominantly observed in both the DSS-treated colons but was 
also observed to some degree in SP colons indicating mild colitis in DSS with SP colons 
that is not detected by assessment of the disease activity index. 
Reduced calcium-induced contraction in murine colitis is restored by SP 
Cumulative addition of CaCl2 induced a concentration-dependent contraction in 
both control and inflamed (DSS treated) distal colon depolarized by Ca2+-free high 
potassium (80 mM) physiological saline solution. DSS treatment significantly (P ≤ 0.01) 
reduced the overall calcium-induced contraction curve (Figure 4.3A, B & C), as 
analyzed by two-way ANOVA (F(1,28)=8.30). In vivo treatment of SP reversed the 
reduced CaCl2-contraction in the DSS treated group (Figure 4.3B & E) without affecting 
the contractility in the control group (Figure 4.3D) (DSS plus SP, F(1,28)=26.65; SP, 
F(1,28)=0.42, two–way ANOVA, n=3 per group). The efficacy of CaCl2 is significantly (P 
≤ 0.001) enhanced by SP treatment in the DSS treated group, unlike in otherwise 
untreated animals. 
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The DSS-induced inflammatory response is reduced by SP treatment 
DSS treatment is known to elicit an inflammatory response that includes the 
recruitment of infiltrating immune cells such as macrophages. As SP treatment is 
expected to be anti-inflammatory we stained colon sections for the presence of 
macrophages. The top row of images of Figure 4.4 (F4/80 plus DAPI) show that 
infiltration of inflammatory macrophages is observed throughout the length of the mouse 
colon after DSS treatment and this is mostly reversed by inclusion of SP in the drinking 
water of mice. Higher magnifications are also shown in the lower rows of images. These 
results confirm that DSS treatment elicits an inflammatory response and that it is at 
least partially reversible with SP. To determine how SP treatment reduced macrophage 
recruitment in DSS-treated colons, gene expression analysis was performed to 
determine the expression of pro- and anti-inflammatory cytokines. As shown in Figure 
4.5, DSS treatment elicited significant increases in the expression of mRNA for the pro-
inflammatory cytokines IL-1β, IL-6 and IL-17A. This increased cytokine expression is 
blocked by the addition of SP to the drinking water. We also assayed for the anti-
inflammatory cytokine IL-37 since this cytokine has been shown to protect the mouse 
colon from DSS induced colitis [140]. However, IL-37 expression was not detected in 
any of the colon samples tested. The observed changes in cytokine expression indicate 
that SP acts by disrupting both the acute phase response and delayed-type immune 
reaction. 
DSS reduced cGMP is blocked by treatment with SP 
To determine if DSS induced inflammation decreases NOS coupling and thus NO 
production we assayed the BH4:BH2 ratio following 7 days DSS treatment. Colonic  
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cGMP levels were also measured at this time as an indirect measure of coupled NOS 
activity. Figure 4.6 shows the results from one experiment where the BH4:BH2 was 
measured at day 7 of DSS treatment. While the trend of lower BH4:BH2 with DSS 
treatment was observed the magnitude of the change never reached statistical 
significance due to the high variability between samples. SP treatment with or without 
DSS, however, increased the BH4:BH2. While we were unable to observe any 
significant change in the BH4/BH2 ratio with DSS treatment, production of cGMP – an 
indirect measure of NO production – was significantly reduced in DSS treated colons 
(Figure 4.7B, P<0.01). The DSS-induced reduction in levels of cGMP was reversed by 
SP treatment. SP alone significantly increased cGMP production relative to control 
animals.   That SP treatment reverses the effect of DSS on colon cGMP levels suggests 
that increased NO generation is required. To further test this mechanism we used the 
sGC inhibitor, ODQ, which is an irreversible inhibitor of sGC. In these experiments, 
ODQ was delivered i.p. on a daily basis with changes in the SP-containing water. As 
shown in Figure 4.7B, ODQ blocked the activity of SP to prevent the decrease in cellular 
cGMP in the colons of mice treated with DSS. Parallel experiments were performed in 
which the DAI of the animals were measured. As shown in Figure 4.7A, ODQ also 
prevented the SP-induced recovery in the DAI of DSS treated animals. 
SP inhibits DSS-induced protein tyrosine nitration 
Previous investigators have termed uncoupled NOS as a “peroxynitrite 
synthase”. Thus if uncoupling of NOS occurs with DSS treatment one would expect 
increased protein Tyr nitration as has been observed in numerous studies with DSS-
induced colitis, e.g. (Yasui et al., 2007; Westbrook and Schiestl, 2010). As shown in  
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Figure 4.8, DSS treatment enhances colonic protein Tyr nitration as detected by  
immunofluorescence and this was abrogated by co-administration of SP. Statistical  
analysis demonstrated a >5-fold increase in nitro Tyr staining relative to DAPI 
fluorescence in the colons from DSS treated animals compared to controls and 
SP+DSS treated animals (p<0.01, n=3 animals per treatment group and 3 images per 
animal). As shown in image N, a magnification of image J, the increased nitro Tyr 
staining was due not only to infiltrating inflammatory cells but also colonic epithelial 
cells. This result along with the observed changes in cGMP and their reversibility by 
treatment with the BH4 precursor, SP, are consistent with uncoupling of NOS in DSS-
induced colitis. 
SP shows protection against AOM/DSS induced adenocarcinoma 
Given that SP protects against the development of DSS-induced colitis we tested 
the hypothesis that this protection may extend to preventing the development of 
AOM/DSS induced CRC. Animals received a dose of AOM followed by three one-week 
courses of DSS with or without SP co-treatment. Following 70-days of treatment, colons 
were excised and assayed morphologically for tumor development.  Individual single 
treatments with AOM or DSS did not induce cancer formation as previously described 
(Neufert et al., 2007). As seen in Figure 4.9A, the combined AOM+DSS treatment 
induced tumor formation that was significantly reduced by co-treatment with SP 
(P<0.05). In the ten animals treated with AOM+DSS as described, the number of tumors 
per distal colon ranged between 2 and 8. The ten animals in the AOM+DSS+SP group 
the number of tumors per colon ranged between 0 and 3. The modest increase (15%) in 
colon length with SP treatment was insufficient to account for the difference observed  
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between the two groups. Interestingly, the SP co-treatment did not decrease the 
average size of those tumors that do develop (Figure 4.9B) suggesting that SP acts to 
limit tumor initiation rather than restricting tumor progression. However, tumors were 
harvested at a relatively late time post-initiation and effects of SP on tumor progression 
would have been missed. 
 
Discussion 
By multiple criteria, we have demonstrated that co-treatment of animals with SP 
counteracts the colitis inducing effects of DSS. Thus SP treatment blocks the increased 
DAI, the loss of microvilli and crypts, and recovers the Ca2+-induced contractility 
responses lost as a consequence of DSS treatment. In addition the experimentation 
demonstrates that SP treatment reduces the inflammatory response measured as either 
increased numbers of infiltrating inflammatory macrophages and neutrophils or 
increased expression of pro-inflammatory cytokines IL-1β, IL-6 and IL-17A. Our studies 
also show that by minimizing inflammation SP also decreased the numbers of tumors 
formed as a consequence of tumor initiation with the carcinogen AOM. 
The initial hypothesis for this study was that DSS treatment would further 
promote the chronic inflammatory environment characteristic of colitis by reducing the 
BH4:BH2 ratio and uncoupling NOS activity resulting in the generation of ROS/RNS. 
However, the observed changes in the colonic BH4:BH2 ratio while consistent with the 
hypothesis were not statistically significant. Although a significant decrease in the 
BH4:BH2 was not measured in the colons from DSS-treated animals, the observed 
changes in cGMP levels and protein Tyr nitration following DSS treatment and their 
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reversibility with SP are consistent with NOS uncoupling. A previous study 
demonstrated that DSS-induced colitis is associated with inhibition of colonic sGC 
activity leading to lower cGMP levels [141, 142].  The underlying mechanism for the 
inhibition was not established but protein levels and mRNA levels of NOS remained 
unchanged. These authors argued that the reduced sGC activity was associated with a 
decreased colonic responsiveness to nitrergic stimuli. More recently a mechanism for 
the inactivation of sGC in inflammatory conditions has been shown to involve oxidation 
of the heme cofactor of sGC [143]. Protection of sGC from oxidative inactivation in vitro 
was achieved by culturing cells with BH4 or its precursors BH2 and SP. This latter 
mechanism can occur without changes in the BH4:BH2 and NOS coupling.  
Measurements of total BH4:BH2 in the whole distal colon do not necessarily reflect 
changes in the different cellular compartments of the colon that may have an impact on 
colitis.  For example, DSS-induced NOS uncoupling in nitrergic neurons by disrupting 
the normal nicotinic-nitrergic communication could by inhibiting cholinergic signaling 
increase secretion relative to absorption and thereby stimulate diarrhea[144]. The 
immunofluorescent images of protein Tyr nitration also suggest localized changes in 
NOS activity with DSS treatment. 
Colitis is a consequence of the relative changes in secretory and absorptive 
functions of the colon that results in changes in gastrointestinal motility. Genetic, 
environmental, microbial and immunological factors all play a role ultimately resulting in 
loss of barrier function and the pathological invasion of inflammatory cells into the 
mucosa and increased expression of inflammatory cytokines. It remains unclear how 
these different factors relate to one another in initiation and progression of colitis and 
   
107 
 
where NO signaling and biopterins such as BH4 and SP contribute to the development 
and prevention of colitis. One mechanism that deserves consideration also involves 
sGC and its role in inhibiting the recruitment of inflammatory cells to sites of tissue injury 
[145]. In endothelial cells sGC activity inhibits inflammatory cell recruitment by blocking 
P-selection expression. Thus besides restoring maintaining barrier function and the 
normal balance of secretion and absorption, SP by protecting sGC from oxidative 
inactivation may also mitigate the effects of DSS-induced colitis by preventing the 
recruitment of inflammatory cells.   
The three cytokines examined, IL-1β, IL-6, and IL-17 have all been associated 
with DSS induced colitis and with colon CRC [146-148]. One unifying feature for all 
three cytokines is their transcriptional regulation by NF-κB [149]. A relatively specific 
inhibitor of NF-κB, dehydroxymethylepoxyquinomicin, inhibits the mRNA expression of 
IL-β, IL-6, TNF-α, IL-12p40, IL-17A and MCP-1 and also suppresses both DSS and 
TNBS-induced colitis.  Our results from studies in Chapter 3 show that SP can inhibit 
NFκB activation and this is potential mechanism of how macrophage infiltration is 
decreasing.  Our lab showed that low inflammatory levels of RNS result in the nitration 
Tyr181 of IκBα, the inhibitor protein of NF-κB, dissociating the complex and facilitating 
translocation of active transcription factor, p65/p50, into the nucleus [25].   SP treatment 
by increasing the BH4:BH2 recouples NOS activity enhancing NO generation and 
reducing RNS generation necessary for Tyr nitration as well as s-nitrosylating p65 
reducing NFκB activity. Thus recoupling of NOS inhibits NF-κB activity leading to 
suppression of the inflammatory response critical for colitis and colitis associated 
carcinogenesis.  The mechanism of SP’s actions is still to be determined but these 
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results suggest a potential approach in mitigating colitis and associated CRC by 
modulating colonic BH4/cGMP metabolism. One potential candidate is a synthetic BH4, 
Kuvan, currently used for treatment of some types of phenylketonuria. Kuvan is also 
being examined in Phase 2 trials for treatment of different inflammatory and vascular 
diseases [150, 151]. 
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Chapter 5 
Perspectives 
 
 Through the course of this dissertation I have identified NOS as uncoupled in 
several tumor cell types both in vitro and in vivo.  The experiments and results here 
have looked at the tumor cell and the inflammatory tumor environment from a new 
perspective of NOS dysregulation.  I have demonstrated that a portion of SP’s effects lie 
in reducing ROS mediated pro-inflammatory signaling in the cell.  Depending on the cell 
type the actual pathways manipulated may be different.   I have demonstrated that by 
reducing the activity of NFκB and STAT3 in MCF-7 cells, SP reduces the pro-survival 
“inflammation begets inflammation” cycle that tumor cells thrive in.  The big question 
remaining is whether the effects we see are mediated by the stromal cells, by direct 
effects on tumor cells or both.  As TAM’s generate large amounts of NO and are more 
than likely the source of the majority of uncoupled NOS (NOSII) in the tumor 
environment, the development of an inducible GTP-CH would be critical in 
understanding the effects of SP.  Other considerations are the role that GTP-CH plays 
in NOS uncoupling and whether SP could be used to remodel vasculature in 
conjunction with other therapeutics. 
Does GTP-CH or SR function as a tumor suppressor gene? 
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  Published results have shown that in some inflammatory disease states, as in 
diabetes mellitus, proteasome dependent degradation of GTP-CHI causes BH4 
deficiencies [152].  We discussed the importance of this previously as the loss of NO 
bioavailability is a cardinal feature of endothelial function.  These researchers 
suggested that inflammation induced ONOO- results in nitration of the 26S proteasome 
resulting in activation.  Low GTP-CH has the same effect on NOS as BH4 oxidation to 
BH2.   
Other researchers have suggested that induction of vascular GTP-CH and 
endogenous BH4 synthesis protect against inflammation induced endothelial 
dysfunction in atherosclerosis.  In this case, BH4 acts a defense mechanism against 
inflammation induced endothelial dysfunction [153].  In our future studies western blot 
analysis of GTP-CH and RT-PCR of tumor tissue and normal tissue can be used to 
determine protein and mRNA levels of GTP-CH.   
There is no evidence of SR reduction or induction in the literature as a response 
to inflammatory stimuli.  However, since SR is necessary for the endogenous synthesis 
of BH4 and for the conversion of exogenous SP to BH4 it may be worth examining in a 
similar fashion. 
SP in vascular normalization or as an adjuvant in treatment 
 The literature has some reports of pro-survival and pro-angiogenic findings in 
tumor cells in the presence of exogenous BH4, and has been shown to be mediated 
through activation of PI3 Kinase [154].  The inhibiting angiogenesis argument stems 
from angiogenesis enhancing tumor vasculature leading to enhanced tumor blood flow, 
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promoting tumor growth.  Dysregulation of angiogenesis occurs in various pathologies 
and is one of the hallmarks of cancer.  The imbalance of pro- and anti-angiogenic 
signaling within tumors creates an abnormal vascular network [155].  These 
abnormalities and the inflammatory microenvironment fuel tumor progression and lead 
to reduction in the efficacy of chemo, radio, and immunotherapy.  The implications of 
enhancing tumor vasculature are of significant importance for the possible 
implementation of combination therapeutic strategies.  Tumors are known to be poorly 
vascularized and this can lead to resistance to some chemotherapeutics.  Normalizing 
the function and structure of tumor vasculature will make the tumor more available to 
drug delivery.  Normalizing tumor vasculature increases oxygen delivery to the tumor 
and as oxygen is a potent radiosensitizer, increases the efficacy of radiotherapy. 
Preliminary studies conducted in our laboratory show that SP may lead to 
enhanced vascularization due to increased presence of blood in the tumor.  In figure 5.1 
we can see that tumors treated with SP are more vascularized compared to control.  
Future studies can be undertaken to determine the extent to which SP would enhance 
the efficacy of current therapeutics. 
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